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1. INTRODUCTION 
“Research is to see what everybody else has seen and to think what nobody else has 
thought” 
 – Albert Szent-Gyorgyi 
  (1893-1986, Hungarian biochemist). 
Human beings being the cherished persons in this world, enjoy the natural wealth, 
but are also suffering from innumerable diseases prevailing from time to time. A selected 
group of people with a great knowledge with super natural powers emerged as 
“Siddhars” who discovered and introduced siddha system of medicine which is a special 
system for the alleviation of sufferings of human beings from diseases. The Siddhars 
wrote their knowledge in palm leaf manuscripts, fragments of which were found in 
different parts of South India. 
In siddha system of medicine, the branch of materia medica has been well 
developed. Purification methods of plants, metals and minerals has been emphasized 
before starting the actual process of medicines which removes the toxic properties of the 
elements used in the preparation of medicine.  
There are about 2,50,000 to 4,00,000 species of flowering plants existing in the 
earth. Plants are the major source of therapeutic agents in all the traditional systems of 
medicine .The earliest use of the medicinal use of plant is found in the ‘Rig Veda’ written 
during 4500 B.C to 1600 B.C.  Medicinal plants are believed to be an important source of 
new chemical substances with potential therapeutic effects .Some of the plants has been 
identified and used in siddha medicines, but many plants require thorough studies for 
their therapeutic value and clinical usefulness. 
WHO support and integrate traditional medicine into national health systems in 
combination with national policy and regulation for products, practices and providers to 
ensure safety and quality; 
• ensure the use of safe, effective and quality products and practices, based on 
available evidence;  
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• acknowledge traditional medicine as part of primary health care, to increase 
access to care and preserve knowledge and resources; and 
• Ensure patient safety by upgrading the skills and knowledge of traditional 
medicine providers.  
So it is needed to prove the efficacy and safety of our medicines by modern scientific 
parameters. 
 
 Chronic inflammatory diseases remain one of the world’s major health problems. 
Inflammation is the response of living tissues to injury. The clinically useful drug against 
pain and inflammation exhibit many adverse effects such as non steroidal anti 
inflammatory drugs [NSAID] causing gastric lesions and also opiates causing tolerance 
and dependence. Pain is defined as “an unpleasant sensory and emotional experience 
associated with tissue damage or described in terms of such damage.” The conventional 
drugs used for pain and inflammation are too expensive or toxic and not commonly 
available to the major people in the world. This leads to great interest in search of safer 
drug for these conditions. 
Siddha system interprets in terms of three elemental theories. The elements of the 
body are called as ‘doshas’. The three humors or doshas namely ‘Vatham, Pitham and 
Kabam’, they normally exist in the ratio 1: 1/2:1/4. Derangement of this ratio leads to 
Vatha, Pitha and Kaba diseases respectively. One of the major Vatha derangements is 
Keel vayu. 
One such disease is Keelvayu which is described in the text ‘Agasthiyar nadi’. The 
types of Keelvayu are mentioned in Noi nadal part 2 refernces taken from Sabapathi 
kaiyedu, the type Azhal keelvayu can be compared with osteoarthritis. 
Arthritis describes many conditions that affect the musculoskeletal system. Most of 
the conditions cause pain, stiffness and swelling of the joints. These symptoms can make 
the the day to day activities like walking up the stairs, difficult to accomplish. 
Osteoarthritis is a form of arthritis that features the breakdown and eventual loss of 
the cartilage of one or more joints. Cartilage is a protein substance that serves as a 
"cushion" between the bones of the joints. Among the 100 different types of arthritis, 
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osteoarthritis is the most common form. Before age 45, osteoarthritis occurs more 
frequently in males. After 55 years of age, it occurs more frequently in females. 
Osteoarthritis commonly affects the hands, feet, spine, and large weight-bearing joints, 
such as the hips and knees. 
  Primary osteoarthritis, osteoarthritis not resulting from injury or disease, is mostly 
a result of natural aging of the joint. With aging, the water content of the cartilage 
increases, and the protein makeup of cartilage degenerates. Eventually, cartilage begins 
to degenerate by flaking. In advanced osteoarthritis, there is a total loss of the cartilage 
cushion between the bones in the joints. Repetitive use of the worn joints can irritate and 
inflame the cartilage, causing joint pain and swelling. Loss of the cartilage cushion 
causes friction between the bones, causing pain and limitation of joint mobility. 
Inflammation of the cartilage can stimulate new bone outgrowths (osteophytes) to form 
around the joints. Osteoarthritis occasionally can develop in multiple members in the 
same family, implying a hereditary (genetic) basis for the condition. 
Secondary osteoarthritis is a form of osteoarthritis, caused by another disease or 
condition. Conditions leading to secondary osteoarthritis include obesity, repeated trauma 
or surgery to the joint structures, congenital abnormalities in joints, gout, diabetes and 
other hormone disorders. 
Obesity leads to osteoarthritis by increasing the mechanical stress on the joint and 
consequently on the cartilage. Next to aging, obesity is the important risk factor for 
osteoarthritis of the knees. Hormonal disturbances, that include diabetes and growth 
hormone disorders, are also associated with secondary osteoarthritis.  
 
While much has been said about the high incidence of diabetes, HIV and cancer 
in India, a recent study suggests that osteoarthritis beats them all to claim the No. 1 spot 
among ailments in India. 
 
OA of the knee is 1 of 5 leading causes of disability among non-institutionalized 
adults.  
  
About 80% of patients with OA have some degree of movement limitation  
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& 25% cannot perform major activities of daily living (ADL’s), 11% of adults with knee 
OA need help with personal care and 14% require help with routine needs. 
 
About 40% of adults with knee OA reported their health “poor” or “fair”. 
• Hip/knee OA ranked high in disability adjusted life years (DALYs) (20) and 
years lived with disability (YLDs). (20)  
There are many internal medicines in siddhha system of medicine, chooranam is one 
among them, and chooranams are fine dry powders of drugs. The term ‘chooranam’ may 
be applied to the powder of a single drug or a mixture of 2 or more drugs, which are 
powdered separately prior to their being mixed to homogeneity. The chooranam should 
be as fine as to be called amorphous and should never be damp. The chooranam has a 
shelf life period of 3 months and should be used with in that period. 
 As per the literature, ‘Vatha nidhanam 800’ Karuvilanchi ver chooranam [Smilax 
zeylanica] the plant belonging to the family Smilaceae is a drug in siddha system which 
is the constituent of many thailam used for the treatment of vatha diseases, and till now 
the plant has not been scientifically validated for its anti inflammatory and analgesic 
activity, so I am interested to scientifically validate Karuvilanchi ver choranam [Smilax 
zeylanica] for Azhal keelvayu [Osteoarthrirtis] and prove its safety and efficacy 
pharmacologically as well as in treating the patients. 
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2. AIM AND OBJECTIVES 
 
Aim:  
 Herbal medicines have a strong traditional value to be used as drugs in terms of 
safety and effectiveness for treating different diseases. There are many herbs which are 
used as rejuvenators as well as for treating disease conditions. Roots of Smilax zeylanica 
are useful to treat osteoarthritis. The goals of osteoarthritis treatment are to reduce pain 
and improve joint function. Currently there is no cost effective treatment to meet these 
goals for a long duration. Hence, my aim is to find a suitable treatment from natural 
product sources for osteoarthritis. 
 The ultimate aim of my dissertation work is to prove the Anti inflammatory & 
analgesic activity and safety of   Karuvilanchi ver chooranam. 
 
Objective: 
The objectives of this dissertation work, is to analyze “Karuvilanchi ver 
chooranam” in the following aspects: 
 To collect the literature review 
 Get the authentication of the raw drug 
 Pharmacognostical study  of the raw drug  
 Phytochemical and Chemical analysis of the trial drug  
 Toxicity study for the safety of the trial drug 
  Pharmacological study to evaluate the anti inflammatory & analgesic 
activity 
 Clinical study to assess the efficacy of the drug through open clinical trial 
in osteoarthritis patients. 
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3. REVIEW OF LITERATURE 
3.1 BOTANICAL ASPECT 
 
Table 3.1 Scientific classification: 
SCIENTIFIC NAME:       Smilax zeylanica Linn 
KINGDOM:                        Plantae  
PHYLUM:                          Magnoliophyta 
CLASS:                              Angiospermae 
ORDER:                             Liliales   
FAMILY:                           Smilaceae 
GENUS:                             Smilax 
SPECIES:                           zeylanica  
 
 
 
Vernacular names: 
 
English:  Rough bind weed. 
Tamil: Ayadi,  Arakkappalai, Arakkappilappi, Aritinpalai, Aritinvayacci, Arkam, 
Arkappilappu, Arucinavayaci, Civakappalai, Civatacu, Curanacini, Irucu 
Irucuppalai, Kal Tamarai, Kamalaiyatticuranacini, Kottarkulavi, Kucciratam 
Kattukodi, Karuvilanchikudam , Malaittamarai, Periyakanni, Payacam, 
Payaci, Payacu, Payaruti, Payatuti, Peruntamarai, Tirunamappalai, 
Varkkaputpam 
    
Sanskrit: Chopachinee , Vanamadhusnuhi 
Hindi: Chobchini, Ramdatun, Jangliaushbah 
Kannada: Kaaduhambu thaavare 
Telugu: Kummeritheega, Kondadantena, Kondagarbhathige, Konda, Sithapa,  
 Kondathaamara, Kumarabaddu, Kushtaputamara. 
Malayalam:    Cherunchakayagavalli, Kalthamara, Karivilanti. 
Marathi: Gholbel, Gutwel, Guti; 
Bengali: Kumarika 
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Fig.3.1.1 Smilax zeylanica 
Smilax - Genus 
A large genus of climbing shrubs distributed in the temperate and tropical regions. About 
24 species occur in India. 
Smilax zeylanica Linn: 
Is a climber with slender 4 – angular branches found throughout the tropical hilly areas 
from the Himalayas southward to Kerala. 
 Stem smooth, striate, armed with a few distant prickles. 
 Leaves alternate, elliptic, lanceolate or ovate, coriaceous, glabrous and used as 
vegetable.  
Flowers in pedunculate many flowered umbels, unisexual;  
Fruit globose berry red when ripe; 
 Roots are eaten for the treatment of venereal diseases and skin troubles and a decoction 
of the bulbous root is given for sores, swellings and abscesses. 
                                                                             (The Wealth of India) 
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Uses 
¾ Roots : 
Used as a substitute for sarsaparilla in the treatment of venereal and skin 
diseases;  
Decoction is given for sores, swellings and abscesses. Leaves consumed as a 
vegetable and applied for rheumatism and pain in the lower extremities, used in 
bloodless dysentery. 
 
¾ Root also used in diseases of nervous system, epilepsy, psychosis, urinary 
disorders, polyuria, wasting diseases, Hemiplegia, Parkinsonism, congenital 
diseases, leprosy and rejuvenator. 
 
¾ Cakes are made by mixing the root juice with powdered seeds of Phaseolus 
mungoand given with warm milk. Salt is not eaten in day meals. 
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3.2 SIDDHA ASPECT 
ngU%l;L thj Fzk;  
“tbTw;w ngU%l;L thjk; tpjkhdJ tJitNa NfS ,dpjha; 
       tskhfNt ,Ufhy; %l;L jd;dpy; tPq;Fk; tYjha; epkpuhjpUf;Fk; 
fbjhfNt nghUe;jplkjpDisT typ fisj;J kpFjpahFk; 
       fhYkjpNy ePU Fj;Jk; Crpiag; Nghy; fL Fz;bdfk; Rs;nsd 
kbahJ FspU gdp cly; cisTk; Nrhk;gYk; khl;Lk; ,U fhy; jupg;Gk; 
       kUtpAly; nkypANk epj;jpiuajpd;wpNa khwhnt jpdk; ngUfp maUk; 
gbePupYW NgHfs; mwpa ntF njsptha; ghL FWKdpapDiuaha; 
       gfU jkpohf ,J cyfwpa XjpNdd; gz;G jkpohfNt jhd;.” 
 
The ‘perumootu vatham’ refers to swelling present in both knee joints, inability to 
move the joint, increasing pain present in the joint, pricking pain in the leg, body pain 
and laziness present, weight loss, insomnia increases and leads to tiredness.  
 
Ff;Flhjp ijyk; 
“fUQ;#iu NtupDl njhyp vL ghtJk; fz;bLk; Mjp%yk; 
     fUtpyhQ;rpf;Flk; Ff;fpy; rjFg;igAk; fupQ;rPuk; Nrq;nfhl;ilAk; 
jUKupa fLFlNd nts;Ss;sp tiff;fpit jhdhW foQ;nrLj;J 
     jg;ghkNy MtpDl ghy;jdpNy miu jwp Jl;L ePf;fpNfhop 
tUkpdpa mjpDila taW jd;dpNy mil tupe;J ijj;jpWf;fp;ajid 
     tskhd epd;gpDl gl;il gyk; md;gJ it GdYgL E}wpNy 
ngUikaha; mdypL FWzpastha; ,W NgR jOjhio rhW 
     gpykhfNt mQ;RgbahfNt vLNgzp vLghz;lk; mjpNy. 
 
gf;FtkjhfNt Ff;Flk; jd;idNa ghz;lkjpy; J}f;fpNajhd; 
     ghfnkhL %bNa rPiykz; Rw;wp eP ghu;j;jLg;Ngw;wp itj;J 
xf;FkdNy ,L nte;J gjkhfNt vL xd;whfNt ,bj;J  
     ciwahd epd;ngz;nza; ,UehopNa tpL Cw;W ehuypd; ghy; mQ;Rgbaha; 
rpf;fhknyhd;wha; fyu;e;jpLg;Ngw;wpNa rpwf;f mdy; Nghl;L fpz;L 
        rPuhfNt nkOfhdJk; gjk; tb guzp rpe;jhjilj;J itj;J 
jf;fgb xUNtis fuz;basNt Fb jFe;j <uhW jpdKk; 
      jtwhj ngU%l;L thjk; jpkpU ePUtypjhd; cisT khWk;”. 
                                                                    Vatha noi nidhanam- 800 
                                                                      Page no. 162, 163,164  
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Root of karunchoorai, 
 Karuvilanchikudam (Smilax zeylanica), 
 Sadhakupai (Anethum graveolens), 
 Karunjeeragam (Nigella sativa),  
Serankottai (Semecarpus anacardium),  
Kadugu (Brassica juncea), 
Vellulli (Allium sativa), 
Each 6 kazhanju taken, mixed with cow’s milk, then kept inside a hen and stitched, and 
boiled. Add neem oil and the oil is prepared properly and when taken internally for 12 
days cures arthritis of bigger joints and pain. 
 The preparations listed below contains Karuvilanchi and used in the treatment of 
vatha diseases. 
CJthjk; 
 ijyk; 
“Nte;jdpd; NjhYk; fUtpyhQ;rpFlk; tps; epd;gk; vl;bg;gl;il  
      NtfKWNk fUq;FwpQ;rpapd; NtuJk; ntt;Ntwha; ,UgynkL 
……………………………………………………………………………………………
……………………………………………………… 
js;shkNy cly; Mjp me;j kpL jtwhnjhW ehSNk 
      jg;ghJ nrd;idapd; gl;ilNahL epd;g njhypjhd; Gdypl;L te;jhy; 
nks;s clypy; NtJ gz;Z kpjNk cJ NkTk; ehs; jtwhkNy 
      NkdpaZfhJly; NehT thj NehTisT NkjpdpaKYk; awpNa.” 
 
 #uzk; 
 
“fUtpyhQ;rpFlk; nfhLNtyp %yTk; fLF kpsfuiz NtU 
     fdpthfNt tif gyk; ehyjha; vL fba ntz;nehr;rpNtu; Njhy; 
……………..…….……………………………………………………...... 
     ghq;fhf cz;L td; gj;jpak; nfhs;S eP gfU Gspkr;rk; js;S 
tUk; clypY}Jkj thjfhkhiyAk; tUk; Nrhif tpr ghfTk; 
      tsH cly; tpiway; tYNehTisT ngUkYk; typj;Jly; NjWk;.” 
                    Vatha noi nidhanam- 800  Page no 150 
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 thj Nfhlhup ijyk; 
“NfhjfyNt thj Nfhlhup ijyk; $WNtd; Nfs;,dp 
    nfhs;Sk; fUq;FwpQ;rpapd; NtuJk; nfhba tpy;iy Njhil Kl;b 
NghjKW nts;shkzf;F fUnehr;rp Ntu; GfnyUf;F ntz;nehr;rpNtu; 
    nghUe;Jk; flyhbNahL vl;bapd; NtUk; Gjpa fUtpyhQ;rp %yk; 
…………………………………………………………………………………… 
…………………………………………………………………………………… 
 
 
nfhs;Sk; fuz;b msthf jpdKk; ,UNtis fzf;fhf <uhW ehs; cz;Zfpy; 
     $Wk; Fly;thjk; Me;jpuKskhe;ij Fk;gthjKld; fus;thjk; 
tps;S jpkpNukTk; gl;rthjq;fSk; tup Fl;lk; #iyAlNd 
     tPuhk; ngse;jpuk; cs;SisT mau;r;irAk; tpl;bLk; ghjk; ntbg;G 
js;Sk; jsu;r;irfs; mk];khuq;fSk; jfu; Royp miuahg;G gpsit 
     jg;ghky; fz;lkhiy glu;jhkiujhd; fpuhzp %yNuhfk; 
ms;Sk; gpsu;e;jpLk; tpg;GUjpahdJk; mf;fuk; Flypy; Gw;W 
     mwpa kNfhjuk; ngUtaW fhkhiy gPyp Md Neha; jPUk;.  
                          Vatha noi nidhanam- 800, Page no 132 
 
Other preparations of Karuvilanchi 
  Ashwa vadham - rasayanam       
 Vatha noi nidhanam- 800 page no.132                                      
 
 Mangisa vadham – kashayam         
Vatha noi nidhanam- 800; page no. 79 
 
 Madhusmini – rasayanam 
Maruthuva aasiriyam page no.5 
 
  Ashwagendhi  - rasayanam    
Maruthuva aasiriyam page no. 79                                          
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Adjuvant: Hot Water 
nte;ePHPd; Fzk;: 
 “thj Fd;k kWQ; #iy 
 rPj Nrj;kQ; rPWQ; Ruk;Nghq; 
 fhJk; Gz;Zq; fz;Ze; jPU 
 %Je; jz;zP Uz;zP Uz;zPNu! 
 kpd;dpa tisf;if ey;yha; 
 kpf;fNjhh; ntd;dPh; jd;id 
 kpd;dpa ,utpw; nfhs;s 
 kyge;jQ; Rj;jp ahFe; 
 Jd;dpa thj gpj;je; 
 Juj;jpL ikaq; jPh;f;F 
 kd;dpa tNuhrp fk;Ngh 
 kf;fpdp jPg khNk! 
¾ Hot water cures peptic ulcer, pain, fever, kapha diseases. When hot water is 
taken in night it relieves constipation. It also cures vatha, pitham and kabam, 
induces appetite. 
“neQ;nrhpg;G new;wpif ePq;fhg; Gspj;Njg;gk; 
    tQ;rkpFk; thjk; tapw;WNeha; - nrQ;nrhyha; 
    tPohky; fl;L kPwpNa fha;e;jeP 
    uhohf;F ef;f tWk;.” 
                                                            -Pathartha guna sinthamani                        
¾ Boiled water cures regurgitation, vatha diseases and diseases of stomach. 
“fha;e;j ePUz;Zq;fhy; fz;nrtp Neha; #iy Fd;kk; 
    Njha;e;j RuNtfe; njhliuak; - gha;e;jlUk; 
    thjj;jpd; Nfhgkpit khWjnkd yhjpaUs; 
    Ntjj;jpd; thf;fpakhk; tps;” 
¾ Boiled water also cures eye, ear diseases, pain, fever, kaba diseases, vatha 
diseases, peptic ulcer. 
¾ On the basis of the above literature evidences, after consulting with the staffs and 
HOD in our department, I have selected hot water as the adjuvant for Azhal 
keelvayu (osteoarthritis) which is one of the vatha diseases. 
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3.3. SIDDHA ASPECT OF THE DISEASE 
 
Azhal keelvayu 
Keelvayu 
Synonyms: 
 Sandhu vali, mootu vali, mega soolai, mudakku vayu, ama vatham. 
Definition 
  Vali kutram afeects the keel or joints and produces disease it is known as keel 
vayu.  In the joints signs of inflammation such as swelling, pricking pain, pain, inability 
to flex the joints, immobile joints will be present; the iyya kutram will also increase and 
produce fever. 
Aetiology 
In siddha system the aetiology for keelvayu is limited within the thridhatu theory. 
The variation of vatham and kabam is the main reason for this disease. The derangement 
occurs under various conditions. 
 They are 
• Physical factors 
• Mental factors 
• Factor of pithamegam 
• Factor of soolai dosham 
• Factor of  ama dosham 
 
Physical factor: 
“tspjU fha; fpoq;F 
     tiutpyh japyy; Nfhio 
KspjapH Nghd; kpFf;F 
     Kiwapyh Tz;b Nfhly; 
FspHjU tspapw; Nwfq; 
     Fdpg;Gw Tyty; ngz;bH 
fspjU Kaf;fk; ngw;NwhH 
     fbnray; fUtpyhkhy;” 
- Sabapathi kaiaedu 
• Ahara and vihara (errors of diets and habits) that give rise to vatha variation i.e. 
excessive intake of certain fruits and roots tend to increase vayu. 
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• Excessive intake of cold substances or exposure to severe cold , exposure to rain, 
fog or mist, cold or breeze, staying in high hills all these are liable to increase 
kabam. On these two essential causes namely vatha and kaba prakobams, keel 
vayu is said to develop. 
Further it is said that excessive sexual indulgence that give rise to mega noi (such as 
Gonorrhea and syphilis) may also produce keelvayu. 
The causes which produce the 15 kinds of soolai including Mega Soolai are as follows: 
“rhu;thd #iy tUkhW Nfsha; 
    jf;f rpiwgl;bUf;Fk; jPikahYk; 
MHthd twr;RL NrhwUe;jhYk; 
    mwTNk rypg;ghAk; XlyhYk; 
jhHthd rig kpFe;j rz;ilahYk; 
    jifthd Jtu;nghrpg;G Gifj;jyhYk; 
NthHthd Nkhfj;jpd; GzHr;rpahYk; 
    kpFe;jgrp AWjypdhYk; #iyahNk” 
Suffering in the jail for a long time, eating dry hot foods, excessive running and 
fighting, excessive intake of astringents, smoking tobacco, excessive cohabitation and 
excessive appetite are the main causes for Soolai. 
 
Mental Factors: 
“Mnkd;w tz;zj;Jf; fpWjp gz;zp 
     Afjp guNjrpfis abj;j NgHf;Fk; 
fhnkd;w fw;Gila kq;if khiuf; 
     fUjpNa kdj;Jspr;rpj;j Ngu;f;Fk; 
thnkd;w tho;kuj;ij ntl;bNdhu;f;Fk; 
    topkwpj;J nghUs; gwpj;J kjpNflu;f;Fk;  
Vnkd;w vr;rpy; jidf; ftu;e;j Ngu;f;Fk; 
    ,fj;jpNy Nehnta;jpr; #iyahNk” 
       Apart from the physical factors, some other mental factors caused the 
derangement of Gunas. The deranged Gunas tend to vitiate the doshas and produce the 
disease.  
Those who sent out the beggars without helping them, those who have sexual 
desire over well characterized ladies, those who cut down the useful trees and those rob 
from passerby; these people are amenable to get this disease. 
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Factor of pithamegam 
According to Agasthiyar vaidhya kandam – 600 ‘pitha megam’ is said as an 
important factor for the causation of Mega Soolai. 
 
“Mr;rpe;j Nkfj;jhy; fghy #lhk; 
     mlq;fhj gPdrj;jp nyl;L tha;T 
%r;rpe;j fhrj;jp yhWtha;T 
     %yjpj yghd tiu %ykhW  
thr;rpe;j tifahd Neha;fnsy;yhk; 
     tskPW NkfNk Neha;fSf;F uh[d; 
ehr;rpe;j Nkfj;jhy; #iygjp ndl;Lk; 
     elj;Jfpw tpj;ijnay;yhk; etpYfpNwhNk 
 
etpyf;Nfs; Nkfj;jhy; gpj;jkhWk; 
     ed;whr;R MNuhrpaq;fs; Ntu;it jhfk; 
et;yf;Nfs; MknkhL gpj;jikak; 
     elg;gpd;wp gpupgpupj;J fkyk; Nghyhk; 
etpyf;Nfs; $Ltpl;L $L ghAk; 
      ehkwpf;Fk; Nkfj;jhy; gpj;j kPwpy; 
etpyf;Nfs; rpuRKj yghdd; tiunte;J 
     ehfndd;w $HkNdhL mghdd; NfNs.” 
 
mghdndd;w Njtj;jjd;jdQ; nraNdhL 
    tuptspf;Fk; tpahdndhL rkhdd; fpupfudhk; 
tghdd;vd;w gpuhzNdhL tha;T gj;Jk; 
    tUk;fh whrh thy;gpd; nry;thu;fs; 
fghdnd;w ape;jpupak; nte;JNghdhy; 
     fyf;fpa jpdj;jpy;; ghrpgw;Wg; NghNyNjf 
kghdndd;w mwpTnfl;L #iy Nuhf  
    kjpNghd;w Njfkij aopf;Fk; ghNu” 
 
In the above stanzas it is said that ‘Megam’ is the chief cause for all diseases 
especially for 8 types of peenisms, 6 types of kasams and 6 types of moolams. By this 
Megam, Megasoolai also occur. In this condition the coordination of vatha, pitha and 
kaba has been broken down. Megam increases pitha and so excessive heat is felt from 
head to apanan. 
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Factor of ama dosham 
  Amam has been defined as a condition in which the first dhatu namely Rasam is 
not properly formed due to lowered strength of ushna (agni). According to some, due to 
the impairment of Agni, the annasaram is not properly formed in the amasayam and it is 
known as amam. 
 When there is impairment of agni, proper transformation of the nutrient 
substances into their respective tissue elements does not take place. 
This primary offending factor ama after provoking the ‘vatha’ travels through 
subtle channels in the body and settles in the joint where in Santhitha kaba resides and 
antagonizes the functions of vatha and kaba resulting in pain, swelling and tenderness, 
restricted movements, malaise , anorexia, fever, constipation or diarrhoea at times. 
 
Classification of keelvayu: 
It is classified into ten types on thridoshic basis. 
They are, 
1. Vali keel vayu 
2. Azhal keel vayu 
3. Iyya  keel vayu 
4. Vali Azhal keel vayu 
5. Vali Iyya  keel vayu 
6. Azhal Vali keel vayu 
7. Azhal Iyya  keel vayu 
8.  Iyya vali keel vayu 
9. Iyya Azhal keel vayu 
10. Mukkutra keel vayu 
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Signs and symptoms: 
 
Prodroma: 
Before the disease starts, first there will be blocking of the nostrils, watering of 
the nose, hoarseness of voice, light fever, pain in the extremities, stabbing and 
excruciating pain in the affected joints. These are the prodromal symptoms which will be 
present. 
 
Symptoms of Azhal keelvayu: 
“gpj;jf;fPy; tha;T jd;dhw; 
  apwq;F fPy; %l;L tPq;fpr; 
rpj;jHnra; kUj;J tj;JQ; 
    rPHglhj; jd;ikj; jhfpj; 
jj;jW fha;r;ry; fz;L 
    rhyNt jidjhd; je;Nj 
nkj;jW rpfpr;ir jd;dhy; 
   nkd;NkYk; ePq;Fkg;gh”      
                                      -  Sabapathi kaiaedu 
 
    When vayu is in vitiated condition if diets which stimulate the pitha are taken, pitha 
keel vayu occurs. In this disease the swelling of the joint increases day by day. As pitha 
increases kaba in the joint decreases and hence dryness occurs. So durig flexation of the 
joint crepitus sound is produced. Sometimes stiffness of the joints occurs and the 
movements become restricted. 
 
Naadi nadai 
¾ Valiiyya  kalappu 
¾ Iyyavali kalappu 
¾ Vali naadi thanithu miguthiyathal 
¾ Valiazhal kalappu 
¾ Iyyaazhal kalappu 
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3.4. MODERN ASPECT OF THE DISEASE 
Osteoarthritis 
Osteoarthritis, also called degenerative joint disease, is the most common type of 
joint disease and is one of the most disabling conditions in developed nations. It is 
characterized by the progressive erosion of articular cartilage. The term osteoarthritis 
implies an inflammatory disease. Although inflammatory cells are present, osteoarthritis 
is considered to be an intrinsic disease of articular cartilage in which biochemical and 
metabolic alterations result in its break down. 
 
In the majority of instances, osteoarthritis appears insidiously, without apparent 
initiating cause, as an aging phenomenon (idiopathic or primary osteoarthritis). In these 
cases, the disease usually affects few joints (oligoarticular) but may be generalized. In 
about 5% of cases, osteoarthritis may appear in younger individuals having some pre 
disposing condition, such as previous macro traumatic or repeated micro traumatic 
injuries to a joint, a congenital developmental deformity of a joint(s), or some underlying 
systemic diseases such as diabetes, ochronosis, hemochromatosis, or marked obesity. In 
these settings, the disease is called secondary osteoarthritis and often involves one or 
several pre disposed joints. Gender has some influence on distribution. The knees and 
hands are more commonly affected in women and the hip in men. 
 
Pathogenesis 
Articular cartilage is the major target of degenerative changes in osteoarthritis. 
Normal articular cartilage is strategically located at the ends of bones to perform 2 
functions: 
(1) Bathed in synofial fluid, it ensures virtually friction – free movements within the 
joint; and 
(2) In weight bearing joints, it spreads the load across the joint surface in a manner 
that allows the underlying bones to absorb shock and weight without being 
crushed. These functions require the cartilage to be elastic and for it to have 
unusually high tensile strength.  
These attributes are provided by the two major components of the 
cartilage:  
 A special type of collagen (type II) and 
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  Proteoglycans, both secreted by chondrocytes. 
 
 As is the case with adult bones, articular cartilage is not static; it undergoes turn 
over in which “worn out” matrix components are degraded and replaced. This balance is 
maintained by chondrocytes, which not only synthesize the matrix but also secrete 
matrix-degrading enzymes. Thus the health of the chondrocytes and their ability to 
maintain the essential properties of the cartilage matrix determine joint integrity. In osteo 
arthritis this process is disturbed by a variety of influences. 
 
The most important of these influences are aging and mechanical effects. Although 
osteoarthritis is not exclusively a wear-and-tear process, there is little doubt that 
mechanical stresses on the joint play a major role in its development. Evidence for this 
includes the increasing frequency of osteoarthritis with advancing age; its occurrence in 
weight bearing joints; and an increase in the frequency of the disease in conditions that 
predispose the joints to abnormal mechanical stresses, such as obesity and previous joint 
deformity. 
Genetic factors also appear to play a role in susceptibility to osteoarthritis, 
particularly in cases involving the hands and hips. The specific gene or genes responsible 
for this have identified, although linkage to chromosomes 2 and11 has been suggested in 
some cases. The risk of osteoarthritis is increased in direct proportion to bone density and 
high levels of estrogens have also been associated with increased risk of the disease. The 
overall role played by hormones in the pathogenesis of osteoarthritis remains unclear. 
Osteoarthritis is characterized by significant changes in both the composition and the 
mechanical properties of cartilage. Early in the course of the disease, the degenerating 
cartilage contains increased water and a decreased concentration of proteoglycans 
compared with healthy cartilage. In addition there appears to be a weakening of the 
collagen network, presumably caused by decreased local synthesis of type II collagen, 
and increased breakdown of preexisting collagen. The levels of certain molecular 
messengers, including IL–1, TNF and nitric oxide, are increased in osteoarthritic 
cartilage and appear to be responsible for some of the changes in the composition of the 
cartilage. Apoptosis is also increased, likely responsible for a decrease in the number of 
functional chondrocytes. In aggregate, these changes tend to reduce the tensile strength 
and the resilence of the articular cartilatge. In response to these regressive changes, 
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chondrocytes in the deeper layers proliferate and attempt to “repair” the damage by 
producing new collagen and proteoglycans. Although theses reparative changes are 
initially able to keep pace with the deterioration of cartilage, molecular signals causing 
chondrocyte loss and changes in the extracellular matrix eventually predominate. Factors 
responsible for this shift from a reparative to a predominantly degenerative picture 
remain poorly understood.  
Morphology 
In the early stages of osteoarthritis, the chondrocytes proliferate. This process is 
accompanied by biochemical changes as the water content of the matrix increases and the 
concentration of proteoglycans decreases. Subsequently, vertical and horizontal 
fibrillation and cracking of the matrix occur as the superficial layers of the cartilage are 
degraded. Gross examination at this stage reveals a granular articular surface that is softer 
than normal.Eventually, full thickness portion of the cartilage are sloughed, and the 
exposed subchondral bone plate becomes the new articular surface. Friction smoothes 
and burnishes the exposed bone, giving it the appearance of polished ivory (bone 
eburnation). Concurrently there is rebuttressing and sclerosis of the cancellous bone. 
Small fractures through the articulating bone are common, and the dislodged pieces of 
cartilage and subchondral bone tumble into the joint, forming loose bodies (joint mice). 
The fracture gaps allow synofial fluid to be forced into the subchondral regions in a one-
way, ball-valve-like mechanism. The loculated fluid collection increases in size, forming 
fibrous walled cysts. Mushroom-shaped osteophytes develop at the margins of the 
articular surface and are capped by fibro cartilage and hyaline cartilage that gradually 
ossify. The synovium shows minor alterations in comparison to the destruction of the 
articular surface and is congested and fibrotic and may have scattered chronic 
inflammatory cells. In severe disease, a fibrous synovial pannus covers the peripheral 
portions of the articular surface.  
Clinical course 
Osteoarthritis is an insidious disease. Patients with primary disease are usually 
asymptomatic until they are in fifties.  If a young patient has significant manifestations of 
osteoarthritis, a search for some under lying cause should be made.  
Characteristic symptoms   
Characteristic symptoms include  
Deep, achy pain that worsens with use;  
21 
 
Morning stiffness;  
Crepitus; and  
Limitation of range of movement. 
Impingement on spinal foramina by osteophytes results in cervical and lumbar 
nerve root compression with radicular pain,  
Muscle spasms,  
Muscle atrophy, and 
Neurologic deficits.   
Typically, only one or a few joints involved, except in the uncommon generalized 
variant. The joints commonly involved include the hips, knees,lower lumbar and cervical 
vertebrae, proximal and distal interphalangeal joints of the fingers, first carpometacarpal 
joints, and first tarsometatarsal joints of the feet. Characteristic in women, but not in 
men, are Heberden nodes in the fingers, representing prominent osteophytes at the distal 
interphalangeal joints. The wrists, elbows and shoulders are usually spared.  
There are still no satisfactory means of preventing primary osteoarthritis, and 
there are no methods for halting its progression. The disease may stabilize for years at 
any stage but more often is slowly progressive over the remaining years of life; 
osteoarthritis is second only to cardiovascular diseases in causing long-term disability.  
 
Investigations: 
                   Laboratory features include the ESR, tests for rheumatoid factor, serum uric 
acid concentration, and appropriate analysis of synovial fluid along with radiography. 
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3.5. LATERAL RESEARCH 
 
1. “Antiulcer activity of Smilax zeylanica linn." 
SP Rao, D Pradhan, 
 Impact: Planta Activa, Vol. 2012, Article ID 
In present study antiulcer activity of hydroalcoholic extract of Smilax zeylanica 
(SZE) roots was investigated in animal model of ulcer. Ulcer was induced by pylorus 
ligation and pylorus ligation with aspirin. SZE produced significant reductive effect on 
ulcer at 100, 200 and 400 mg/kg. Efficacy was assessed on the basis of total gastric 
volume, pH, total acidity, free acidity, and ulcer index and percentage protection. It was 
observed that SZE significantly (P<0.05) reduced level of all parameters assessed in 
present investigation. From this study it can be concluded that hydroalcoholic extract of 
roots of Smilax zeylanica possess significant antiulcer activity. 
2.  Pesticidal activity of Smilax zeylanica L. extracts on Cryptolestes pusillus 
(Schon.) (Coleoptera: Cucujidae) 
MA Bari, W Islam, AR Khan 
Journal of Bangladesh Academy of Sciences, Vol. 34, No. 2, 201-203, 2010 
The chloroform and methanolic extracts of Smilax zeylanica L. were assessed for 
mortality against the adults of flat grain beetle, Cryptolestes pusillus (Schon.) under 
laboratory conditions by the surface film method. The methanolic extracts caused 
significantly high (p < 0.001) mortalities than the chloroform extracts. Results obtained 
show the potential of using S. zeylanica extracts for C. pusillus management. 
3. Evaluation of antioxidant potential of Smilax zeylanica L in reversing haloperidol 
induced catalepsy in rats. 
Rasheed ahmed S et al. 
International journal of pharmacy and pharmaceutical sciences, vol 4, suppl 3, 2012. 
4.  In- Vitro and In-Vivo Antioxidant Activity Studies on the Leaves of Smilax 
zeylanica L. (Smilacaceae) 
Anita Murali et al. 
Journal of Pharmacy Research, Vol 3, No 10 (2010) 
In the present study, in vitro and in vivo antioxidant studies were performed on 
the leaves of Smilax zeylanica L. Methanol and aqueous extracts of the drug were 
evaluated for in vitro antioxidant activity using DPPH, hydrogen peroxide, ABTS, nitric 
oxide and superoxide free radicals. The plant extracts exhibited dose dependent 
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scavenging effects against the different free radicals tested. The methanol extract 
(SZLM) was subjected to in vivo antioxidant activity studies using CCl4 induced 
hepatotoxicity model in Wistar albino rats. The extract (SZLM) exhibited significant 
increase in the levels of glutathione, tissue proteins and enzymes viz. SOD, catalase and 
peroxidase at different dose levels. The extent of lipid peroxidation was significantly 
reduced in the extract treated groups. Results were comparable with that of standard 
antioxidant silymarin. 
5. Antidiabetic activity of methanolic extract of Smilax zeylanica Linn in 
streptozotocin induced diabetic rats 
Rajesh, V.; Perumal, P.; Sundarrajan, T. 
Internet Journal of Endocrinology; 2010, Vol. 6 Issue 1, p2 
6. In-Vitro Evaluation of Smilax Zeylanica Linn. Leaves for Anthelmintic Activity 
V. Rajesh et al. 
The Internet Journal of Pharmacology, 2010 Volume 9 Number 1. DOI: 10.5580/797 
The objective of the present study was to evaluate the in-vitro anthelmintic 
property of various solvent extracts of Smilax zeylanica leaves against Pheritima 
posthuma. Various concentrations of Petroleum ether, Benzene, Chloroform and 
Methanol extract (20mg/ml and 40mg/ml) were used in evaluation. The activity was 
assessed by the determination of time of paralysis and time of death of worms. 
Albendazole (20mg/ml) was included as a reference standard. All the extracts were found 
to paralyze and kill the worms. The Petroleum ether extract and Chloroform extract 
showed a potent anthelmintic activity compared to standard drug albendazole. Benzene 
extract was less potent to cause paralysis and death at 20mg/ml and 40mg/ml, which took 
more time to paralyze and death. Methanol extract was less potent to cause paralysis at 
20mg/ml and 40mg/ml, but caused death of worms earlier than albendazole. It is 
concluded that the anthelmintic efficacy of solvents extracts of Smilax zeylanica might be 
attributed to the presence of phytochemicals. 
7. Anti epileptic activity of alcohol and aqueous extracts of roots and rhizomes of 
Smilax zeylanica 
V.Madhavan et al. 
Pharmacologyonline 
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4. MATERIALS AND METHODS 
4.1. PREPARATION OF CHOORANAM: 
Material: 
Roots of Smilax zeylanica (Karuvilanchi ver) 8kg of Fresh roots were taken, and 
then it was shade dried after that the net weight of the roots were around 1.5 kg. 
 
Collection and Authendication of the materials: 
 The plant material used in this study was collected during the month of June 
(2012) from Kanyakumari Dist, Tamilnadu, India and authenticated from the Gunapadam 
experts in, Govt. siddha medical college, Chennai-106 and Certified from Botanist, 
Central Research Institute For Siddha, Arumbakkam, Chennai-106.  
Purification of the Raw Drug: 
 The plant roots were well rinsed in water to remove the impurities. Then the roots 
were cut into pieces and dried in shade. 
Preparation of the chooranam: 
 The well dried Smilax zeylanica (Karuvilanchi ver) were made into fine powder. 
The finest physical form of this drug was obtained when the powdered material is sieved 
through a white cotton cloth (Vashthirakayam). 
 
Purification of chooranam: 
 The Chooranam was moistened with cow’s milk. The pot was half filled with 
milk and water. The mouth of the pot was covered and tied with white cotton cloth. The 
Chooranam (moistened by milk) was placed above the tied cloth. The mouth of the pot 
was closed with another mud pot. The gap between the two mud pots was tied using a 
wet cloth to avoid evaporation. Then this arrangement was kept on fire and boiled until 
water level gets reduced in the lower pot. Then the powder was taken, dried, powdered 
finely and preserved for usage. 
 
Preservation:  
 The purified Chooranam was stored in a clean, air tight glass container. Since the 
shelflife period of the Chooranam is only three months, the prepared Chooranam must 
be used within 3 months period.  
Administration of the drug: 
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 Form of the medicine  : Chooranam 
 Route of Administration : Enteral 
 Dose    : 1gm 
 Anubanam (Vehicle)  : Warm water 
 Times of Administration : Two times a day; after food 
 Duration    : 7 weeks 
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Fig.4.1.1 Dry root of Smilax zeylanica 
 
 
 
 
                                  Fig 4.1.2 Karuvilanchi ver chooranam 
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4.2. STANDARDIZATION OF THE DRUG 
4.2.1. PHARMACOGNOSTIC ASPECT: 
Collection and authentication of the materials: 
Plant specimen for the proposed study were collected from Kanyakumari Dist and 
identified and authenticated by the Gunapadam experts in Department of P.G. 
Gunapadam, Govt. Siddha medical college, Chennai – 106 and certified by Botanist, 
Central Research Institute for Siddha, Chennai – 106. Care was taken to select healthy 
plants and normal roots.  
Staining: 
The required samples of the root were cut and removed from the plant and fixed 
in FAAsolution (70% ethyl alcohol, formalin and acetic acid in the ratio of 90 ml: 5 ml: 5 
ml).  After 24 hrs of fixing, the specimens were dehydrated with graded series of Tertiary 
–Butyl alcohol as per the schedule given by Sass, 1940. Infiltration of the specimens was 
carried by gradual addition of paraffin wax (melting point 58-60 C) until TBA solution 
attained super saturation. The specimens were cast into paraffin blocks. 
 
Sectioning 
The paraffin embedded specimens were sectioned with the help of Rotary 
Microtome. The thickness of the sections was 10-12 μm. Dewaxing of the sections was 
by customary procedure (Johansen, 1940). The sections were stained with Toluidine 
blue as per the method published by O’Brien et al. (1964). Since Toluidine blue is a 
polychromatic stain. The staining results were remarkably good; and some cytochemical 
reactions were also obtained. The dye rendered pink colour to the cellulose walls, blue to 
the lignified cells, dark green to suberin, violet to the mucilage, blue to the protein 
bodies etc.  
 
Photomicrographs 
Photographs of different magnifications were taken with Nikon lab photo 2 
microscopic Unit. For normal observations bright field was used. For the study of 
crystals, starch grains and lignified cells, polarized light was employed. Since these 
structures have birefringent property, under polarized light they appear bright against 
dark background. Magnifications of the figures are indicated by the scale-bars. 
Descriptive terms of the anatomical features are as given in the standard Anatomy books 
(Esau, 1964). 
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4.2.2. PHYSICO-CHEMICAL ANALYSIS: 
Procedures: 
Total ash  
Two grams of grounded air-dried material was accurately weighed in a previously 
ignited and tared silica crucible. The drug was gradually ignited by raising the 
temperature to 450°C until it was white. The sample was cooled in a desiccator and 
weighed. The percentage of total ash was calculated with reference to air-dried drug. 
Acid Insoluble ash  
The ash was boiled with 25 ml of 2 M hydrochloric acid for 5 minutes, the 
insoluble matter was collected on an ash less filter paper, washed with hot water, ignited, 
cooled in a desiccator, and weighed. The percentage of acid insoluble ash was calculated 
with reference to the air-dried drug. 
Water Soluble ash  
The ash was boiled with 25 ml of water for 5 minutes, the insoluble matter on ash 
less filter paper collected, washed with hot water, ignited, cooled in a desiccator, and 
weighed. The weight of the insoluble matter from the weight of the total ash was 
subtracted; the difference represents the water soluble ash. The percentage of water 
insoluble ash was calculated with reference to the air-dried drug. 
 
Loss on drying: 
 3gm of the drug is heated in a hot oven at 1050 c to constant weight. The % of 
weight was calculated. 
Potential of hydrogen (pH): 
 The pH scale is logarithmic and runs from 0.0 to 14.0 with 7.0 being neutral. 
Readings less than 7.0 indicate acidic solutions, while higher readings indicate alkaline 
or base solutions.  
Above mentioned Quantitative analysis results are showed in the Table 4.2.2.1 
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Thin layer chromatography: 
 Solvent system: 
Toluene: Ethyl acetate (4:1.5). 
TLC plate: 
  Aluminium plate precoated with silica gel 60F254 of 0.2 mm thickness (Merck). 
Developing chamber: 
 Camag’s twin trough chamber. 
Visualizing reagent: 
 Vanillin-sulphuric acid reagent. 
Extract Preparation:  
4 g of the chooranam was soaked overnight in chloroform. Boiled on a water bath 
for 10 mins, filtered and concentrated to 10 ml.  
Procedure: 
 The extract was applied on the TLC using capillary and developed in the solvent 
system.  The developed TLC plate was air dried and photograph was taken in white light. 
Then dipped in vanillin-sulphuric acid reagent, heated in an oven at 105°C until the 
development of coloured spots and photograph taken. 
 
4.2.2.3. SCANNING ELECTRON MICROSCOPE (SEM): 
The Scanning Electron Microscope (SEM) is a microscope that was electrons 
rather than light to form an image. There are many advantages in using the SEM instead 
of a light microscope. 
Resolution : 1.2 nm gold particle separation on a carbon substrate 
Magnification: From a min of 12 X to greater than 1, 00,000 X 
 
The SEM has a large depth of field, which allows a large amount of the sample to 
be in focus at one time. The SEM also produces images of high resolution, which means 
that closely spaced features can be examined at a high magnification. Preparation of the 
samples is relatively easy since most SEM one require the sample to be conductive. 
The combination of higher magnification, larger depth of focus, greater 
resolution, and easy of sample observation marks the SEM one of the most heavily used 
instruments in research areas today. 
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4.2.2.4. FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR) 
Instrument Details: 
Model   :  Spectrum one: FT-IR Spectrometer                                   
Scan Range   :  MIR 450-4000 cm-1                                                          
Resolution   :  1.0 cm-1                                                                                 
Sample required :  50 mg, solid or liquid.                                           
Fourier Transform Infrared Spectroscopy (FTIR) is an analytical technique used 
to identify mainly organic materials. FTIR analysis results in absorption spectra which 
provide information about the chemical bonds and molecular structure of a material. The 
FTIR spectrum is equivalent to the "fingerprint" of the material and can be compared 
with cataloged FTIR spectra to identify the material. 
Fourier transform infrared spectroscopy analytical capabilities: 
• Identifies chemical bond, functional groups by the absorption of infrared radiation 
which excites vibrational modes in the bond 
• Especially FTIR is capable of identifying the chemical bonds of organic materials  
• Detects and Identifies organic contaminants  
• Identifies water, phosphates, sulphates, nitrates, nitrites, and ammonium ions  
• Detection limits vary greatly, but are sometimes <1013 bonds/cm3 or sometimes 
sub monolayer  
• Useful with solids, liquids, or gases  
 To confirm the acid and basic radicals of the trial drug inorder to ensure the 
inorganic constituents 
 
4.2.3. QUALITATIVE PHYTOCHEMICAL ANALYSIS: 
Materials and methods:                        
• The roots of Smilax zeylanica were washed and shade dried.  
• The roots were then milled to obtain the fine powder using an electric 
blender.  
• The yield of extract was calculated. 
• Phytochemical screening procedures were carried out to determine the 
biologically active compounds that contribute to the flavour, colour and 
other characteristics of roots. 
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Table. 4.2.3. Qualitative phytochemical analysis: 
 
S.NO EXPERIMENT OBSERVATION INFERENCE 
I. 
Test for Tannins: 
   Substance is shaken with water and 
added with lead acetate solution 
Forms a white precipitate Presence of tannins 
II. 
Test for Saponin: 
    To a few mg of extract distilled 
water is added and shaken well. . 
The formation of foam 
occurs 
Presence  
of saponin 
III. 
Test for Flavonoids: 
    Substance is dissolved in alcohol, 
added with magnesium bits and 
concentrated hydrochloric acid, and 
heated over a water bath. 
The appearance of majenta 
colour 
Presence  
of flavonoids 
 IV. 
Test for steroids: 
The sample 2ml is mixed with 2 ml 
H2SO4 and 0.5 gm Acetic anhydride. 
 The solution turns in to 
blue to green colour 
Presence  
of Steroids 
V. 
Test for Cardiac glycoside (Keller-
Killani Test) 
Add 2 ml of glacial acetic acid 
containing a drop of ferric chloride 
solution and 0.5 ml of concentrated 
sulphuric acid to the chloroform 
extract of the plant. 
Absence of the blue color 
in the acetic acetic acid 
layer 
Absence of cardiac 
glycosides 
VI. 
Test for Triterpenes:(Noller’s Test)
   To few mg of extract, add tin and 
thionyl chloride and heat in water 
bath. 
Presence of purple colour 
Presence    
of Triterpenes 
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S.NO EXPERIMENT OBSERVATION INFERENCE 
VII.. 
Test for Alkaloids (Dragendorff’s 
Test)  
Few mg of extract in separate test tube 
was warmed with 2% Sulphuric acid 
for 2 minutes. And it was filtered in 
separate test tube and few drops of 
Dragendorff’s reagent were added.   
 
The presence of orange red 
precipitate 
 
 
 
Presence 
of alkaloids 
 
 
 
VIII. 
Test for Phenolic compounds: 
   Substance in water is added with 
 5 % alcoholic ferric chloride.  
 
The presence of dark blue 
or green colour 
Presence of 
phenolic 
compounds 
IX. 
Test for Coumarins: 
To 1 ml of extract, 1ml of 10% 
NaOH was added. 
 
Absence of  Formation of 
yellow color 
Absence of 
coumarins 
X. 
Test for  Anthraquinones 
Few milligram of crude powder is 
shaken with 10 ml of benzene and 
filtered. To this filtrate, 0.5 ml of 10 
% ammonia solution is added and the 
mixture is shaken well. 
Absence of  of the violet 
colour in the layer 
Absence of 
anthraquinones 
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Herbal based plant products can be exploited with sustainable comparative and 
competitive advantage. Higher plant, being sources of medicinal compounds continue to 
play dominant role in maintaining human health since antiquities. Over 50% of all 
modern clinical drugs are of natural plant origin. (Stuffness and Douros, 1982). 
 
4.2.4. PROXIMATE CHEMICAL ANALYSIS  
Methodology for Chemcial Analysis 
Preparation of Extract: 
o Add 5 gm of the Karuvilanchi ver chooranam to 50ml of distilled water. 
o Boil the solution for 20 minutes, cool and then filter.  
o The extract is used for the following tests. 
 
Table 4.2.4 Methodology for chemcial analysis 
 
S.No Experiment Observation Inference 
1. 
Test for reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, 
then boil for two minutes 
Absence of Green / 
Yellow / Red 
Precipitate 
Absence of 
Reducing Sugar 
2. 
Test for Starch : 
To 5 ml of extract add 2ml of acetic 
acid and then add few drops of 
N/50 Iodine Solution. 
Presence of Blue 
Colour 
Presence of 
Starch 
3. 
Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate Solution. 
Presence of Violet 
or Purple Colour 
Presence of 
Proteins 
4. 
Test for amino Acid : 
Place 2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same 
and allowed to dry. 
Absence of  Violet 
Colour 
Absence of 
Amino Acid 
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S.No Experiment Observation Inference 
5. 
Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch’s reagent. 
Absence of  Yellow 
Precipitate 
Absence of  
Albumin 
6. 
Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution and 
2ml of concentrated Nitric Acid. 
Absence of Yellow 
Precipitate 
Absence of 
Phosphate 
7. 
Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
Absence of White 
Precipitate 
Absence of 
Sulphate 
8. 
Test for Chloride :  
Add 2ml of extract to dilute nitric 
acid till the effervescence ceases. 
Then add 2 ml of Silver Nitrate 
Solution. 
Absence of Cloudy 
White Precipitate 
Absence of 
Chloride 
9. 
Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thio cynate solution and 
add 2ml of concentrated Nitric 
Acid. 
Presence of Red 
Colour 
Presence of Iron 
10. 
Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
Absence of White 
Precipitate 
Absence of 
Calcium 
11. 
Test for Sodium : 
Make a paste with 2 pinches of the 
sample with Hcl and Introduce it 
into the blue flame.  
Absence of Yellow 
Flame 
Absence of 
Sodium 
12. 
Test for Potassium : 
Add a pinch of the sample to 2 ml 
of Sodium Nitrate Solution. Then 
add 2ml of Cobal Nitrate in 20% 
acetic acid. 
Absence of Yellow 
Precipitate 
Absence of 
Potassium 
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S.No Experiment Observation Inference 
13. 
Test for Zinc : 
To 2ml of extract, add few drops of 
Sodium Hydroxide. 
Absence of White 
Precipitate 
Absence of Zinc 
14. 
Test for Magnesium : 
To 2ml of extract, add few drops of 
Sodium Hydroxide Solution 
Absence of White 
Precipitate 
Absence of 
Magnesium 
15. 
Test for Alkaloids : 
a. To 2ml of extract, add 2ml 
of Potassium Iodide 
Solution 
b. To 2ml of extract add 2ml 
of Picric Acid. 
c. To 2 ml of extract add 2ml 
of Phosphotunqstic Acid. 
Presence of 
Red Colour 
 
Presence of 
Yellow Colour 
 
Presence of  
White Precipitate 
 
Presence of 
Alkaloids 
 
Presence of 
Alkaloids 
Presence of 
Alkaloids 
16. 
Test for Tannic Acid : 
To 2ml of extract add 2 ml of Ferric 
Chloride Solution 
Presence of  
Black Precipitate 
Presence of 
Tannic Acid 
 
 
4.3. TOXICITY STUDY  
Materials and methods: 
Animals  
 Albino mice (22–28 g) and Wistar rats (180–200 g) either sex were obtained from 
the animal house of animal housing facility of department of pharmacology, Vels 
University, Chennai. Animals were maintained at standard laboratory conditions and fed 
with standard feeding pellets (Sai durga foods, Bangalore). Prior to treatment, the 
animals were fasted for 10 and 12 h respectively. However, water was made available ad 
libitum. (Approval number: XIII/VELS/PCOL/16/2000/CPCSEA/IAEC/08.08.2012). 
Experimental Methods 
Acute toxicity 
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 Acute oral toxicity test for the Karuvilanchi ver chooranam was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. The 
test substance is administered in a single dose by gavage using a stomach tube or a 
suitable intubation cannula. The fasted body weight of each animal is determined and the 
dose is calculated according to the body weight. After the substance has been 
administered, food was withheld for a further 2 hours in mice. The animals were 
observed continuously for the first 4 h and then each hour for the next 24 h and at 6 
hourly intervals for the following 48 h after administering of the test drug, to observe any 
death or changes in general behaviour and other physiological activities. Single animals 
are dosed in sequence usually at 48 h intervals.  
  However, the time interval between dosing is determined by the onset, 
duration, and severity of toxic signs. Treatment of an animal at the next dose was delayed 
until one is confident of survival of the previously dosed animal. General behavior, 
respiratory pattern, cardiovascular signs, motor activities, reflexes, change in skin and 
fur, mortality and the body weight changes were monitored daily. The time of onset, 
intensity, and duration of these signs, if any, was recorded.  
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4.4. PHARMACOLOGICAL STUDY: 
Drugs and chemicals 
Formalin, acetic acid, and CMC, all from Sigma-Aldrich Chemicals were the chemicals 
used. The standard drugs aspirin and Pentazocine was procured from the local market. 
All the other chemicals and drugs used were of analytical grade. 
 
Evaluation of analgesic activity by Eddy’s Hotplate method 
 The hot-plate test method was employed to assess the analgesic activity. The 
temperature of the cylinder was set at 55±0.50C. The experimental mice were divided 
into four groups. Each mouse acted as its own control. Prior to treatment, the reaction 
time of each mouse (licking of the forepaws or jumping response) was done at 0 and 
10min interval. The average of the two readings was obtained as the initial reaction time. 
The reaction time following the administration of the Karuvilanchi ver chooranam (250, 
500 mg/kg, p.o.), Pentazocine (5mg/kg) and Saline (p.o.), was measured at 30, 60and 120 
minutes after a latency period of 30 mins. The Percentage analgesic activity was 
calculated. 
Antinociceptive testing 
 The antinociceptive property of Karuvilanchi ver chooranam was tested using the 
model of writhing response in mice. Swiss albino mice of either sexes weighing 20-30 g 
were used. The writhing syndrome was elicited by an intraperitoneal injection of 0.7% 
acetic acid at the dose of 0.1ml/10 g body weight. Test substances and control vehicle 
were orally administered into the mice 30 min before acetic acid and the number of 
writhes was noted for 25 min beginning 5 min after acetic acid injection. 
 
Evaluation of acute anti-inflammatory activity by plethysmometer method 
 Karuvilanchi ver chooranam Suspended with 2% carboxy methyl cellulose was 
prepared and the stock solution concentration was 200mg/ml. The animals were divided 
into four groups. Acute inflammation was produced by subplantar injection of 0.1 ml of 
1% suspension of formalin in normal saline in the right hind paw of the rats. Paw volume 
was measured plethysmometrically at '0' –‘2' hours after formalin injection. The animals 
were treated with Karuvilanchi ver chooranam (250, 500 mg/kg., orally). Saline (3 
ml/kg, orally) treated animals served as control and acetyl salicylic acid (100 mg/kg, 
38 
 
orally) was administered as standard drug. The drugs were administered simultaneously 
with formalin injection. Mean increase in paw volume was measured and Percent 
inhibition of test drugs was calculated in comparison with vehicle control (100%).  
Statistical data 
 Data were presented as mean ± S.E.M. Statistical differences between control and 
treated groups were tested by one way ANOVA followed by dunnet’s test. 
4.5. CLINICAL ASSESSMENT: 
Nowadays Life style has changed in many ways. Sedentary Lifestyle and lack of 
exercise are also responsible for osteoarthritis.  I have selected Karuvilanchi ver 
chooranam, a herbal medicine for this clinical trial to prove its safety and efficacy 
against Osteoarhritis. 
Objectives 
 The study was conducted on Osteoarhritis patients to assess the anti inflammatory 
and analgesic activity of “Karuvilanchi ver chooranam” clinically, both in-patients and 
out-patients of both sex and varying age groups.  
Study Centre 
 The clinical study for osteoarhritis is carried out in outpatient department and in 
patient ward of Govt.Siddha medical college hospital and Arignar Anna Indian Hospital, 
Arumbakkam, Chennai-106. 
Design of the study: 
Open clinical trial, Phase II B  
Selection: 
 50 patients from both sexes of various age groups were selected for clinical trial. 
Among 50 patients 40 patients were treated as out-patients, 10 patients were treated as in 
patients. The selection was based on the inclusion and exclusion criteria.  They were 
clinically diagnosed on the basis of siddha principles with modern laboratory findings. 
 
Registration Process 
To register a patient, the following documents are required 
¾ Copy of required laboratory tests 
¾ Signed patient consent form 
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 I verified the eligibility and assigned a patient study number, drug dose and registered 
the patient on the study. 
Criteria selection: 
Criteria for inclusion: 
Patients with osteoarthritis are eligible for entry to the trial if the following criteria are 
satisfied. 
The criteria of inclusion are: 
♦ Morning stiffness 
♦ Pain  
♦ Swelling 
♦ Restricted range of movements 
♦ Radiological findings of OA 
♦ Algo functional index above 7 
♦ Co operative patients 
♦ The previous drug regimen if any have been with held for 24 hours before the clinical 
trial. 
Criteria for exclusion: 
♦ Rheumatoid arthritis 
♦ AIDS 
♦ Malignancy 
♦ Pregnant and lactating women 
♦ TB 
♦ Renal diseases 
♦ Cardio vascular disorder 
♦ Age below 10 years 
♦ Syphilis 
 
Withdrawal criteria: 
Patients were removed from study when any of the criteria listed below applies. In the 
absence of treatment delays due to adverse events, treatment may continue for 2 cycles or 
until one of the following criteria applies: 
♦ Disease progression, 
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♦ Deterioration of vital signs with cardiac, respiratory, hepatic, renal and 
CNS changes. 
♦ Intercurrent illness that prevents further administration of treatment, 
♦ Unacceptable adverse event(s), 
♦ Patient decides to withdraw from the study, or  
♦ General or specific changes in the patient’s condition render the patient 
unacceptable for further treatment in the judgment of the investigator. 
 
Routine examination and assessment: 
¾ The full details of history and physical examination of the patients were 
recorded as per the proforma .The clinical assessment was done initially at the 
end of every week during treatment and at the end of the follow up. The 
laboratory investigation and the physiological parameters were recorded 
initially at the end of the treatment and at the end of follow up as per the 
proforma. 
Dosage: 
The trial drug Karuvilanchi ver chooranam was given in the dose of 1gram with 
hotwater depending upon the severity of the case. 
 
Administration of the drug: 
 Form of the medicine  : Chooranam 
 Route of Administration : Enteral 
 Dose    : 1g  
 Anubanam (Vehicle)  : Hot water 
 Times of Administration : Two times a day; after food 
 Duration   : 7 weeks 
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Diet restriction and medical advice: 
♦ The patients were instructed to take easily digestible foods. 
♦ They were advised to take, healthy food. Avoid bitter gourd, agathi greens, 
brinjal, and non-vegetarian diet. 
♦ The patient was advised to avoid cold damp climate. 
♦ The patient was advised to take rest. But prolonged immobilization should be 
avoided. 
♦ The clinical improvement was observed and recorded in the proforma of case 
sheet. 
 
Trial conduct: 
The study was conducted in compliance with the protocol approved by the 
Institutional Review Board, and according to Good Clinical Practice standards. No 
deviation from the protocol was implemented without the prior review and approval of 
the IRB. 
 
Classification of results 
1. Good Response 
a. Relief of Symptoms above 75% 
b. Laboratory parameter findings towards normalcy. 
2. Fair Response 
a. 50% to 75% relief in symptoms. 
b. Significant improvement in laboratory parameter. 
3. Poor Response 
25% to 49% relief in symptoms and minimal improvement in laboratory 
parameters. 
4. No Response 
No relief in symptoms and no significant improvement in laboratory 
parameters. 
Follow up: 
Assessment was done every three days before treatment and after treatment. 
During this period clinical assessment and laboratory investigation was carried out. 
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Statistical analysis 
The data will be tabulated and analyzed by students ‘T’ test. 
Ethical review 
The protocol and any amendments were submitted to Govt siddha medical 
college, Chennai – 106 (IEC) and got formal approval to conduct the study. The decision 
of the IEC concerning the conduct of the study was made in writing to the investigator. 
All subjects for this study was provided a consent form describing this study and 
provided sufficient information for subjects to make an informed decision about their 
participation in this study. This consent form was submitted with the protocol for review 
and approval by the IEC. The formal consent of a subject, using the IEC-approved 
consent form, was obtained before that subject was submitted to any study procedure. 
This consent form was signed by the subject or legally acceptable surrogate, and the 
investigator-designated research professional obtaining the consent. 
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4.5.1.1 Clinical study of Karuvilanchi ver chooranam in osteoarthritis 
Sl.No. O.P. No. Name Age/ Sex Date of first visit Symptoms Date of last visit Results 
1. 5852 KUMAR 45/M 11.6.2012 
Pain ⊕ in both knee  joints, 
morning stiffness ⊕ 1.11.2012 
 
FAIR 
2. 5807 VALLIAMMAL 55/F 11.6.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 4.9.2012 GOOD 
3. 8053 RAMADAS 60/M 20.6.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 6.8.2012 GOOD 
4. 851 MISBARA 57/F 28.6.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 5.11.2012 GOOD 
5. 2698 MALLIGA 60/F 3.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 6.9. 2012 GOOD 
6. 2764 MANIKKAM 60/M 5.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 18.9.2012 GOOD 
7. 3228 REVATHI 45/F 7.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 1.11.2012 GOOD 
8. 4000  JAYASHREE 35/F 10.7.2012 
Pain ⊕ in both knee  joints, 
morning stiffness ⊕ 5.9.2012 GOOD 
9. 4443 VIJAYALAKSHMI 45/F 12.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 9.9.2012 GOOD 
10. 6290 BANUMATHI 59/F 19.7.2012 
Pain ⊕ in both knee  joints, 
morning stiffness ⊕ 5.9.2012 FAIR 
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4.5.1.2. Clinical study of Karuvilanchi ver chooranam in osteoarthritis 
Sl.No. O.P. No. Name Age/ Sex Date of first visit Symptoms Date of last visit Results 
11. 7545 ANANDAN 53/M 24.7.2012 
Pain & swelling in left knee joint,  
morning stiffness ⊕ 
 
22.11.2012 
GOOD 
12. 7590 MOHAMMED EHIYA 61/M 24.7.2012 
Pain ⊕ in both knee  joints, 
morning stiffness ⊕     
 
7.12.2012 
FAIR 
13. 7656 SUBRAMANIUM 68/M 24.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 
  
5.10.2012 
GOOD 
14. 8738 SHANTHI 48/F 28.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 
 
8.11.2012 
GOOD 
15. 8830 SRINIVASAN 45/M 29.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 
 
4.9.2012 
GOOD 
16. 8856 SAGHADEV1 43/F 29.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 
 
18.9.2012 
GOOD 
17. 9197 RAGOTHAMAN 62/M 30.7.2012 
Pain ⊕ in both knee  joints, 
morning stiffness ⊕     
 
2.9.2012 
GOOD 
18. 125 SHANTHI 48/F 2.8.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 
 
15.9.2012 
FAIR 
19. 515 VIJAYALAKSHMI 45/F 4.8.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 19.9.2012 GOOD 
20. 528 KANCHANA 60/F 4.8.2012 
Pain ⊕ in both knee  joints, 
morning stiffness ⊕     20.11.2012 GOOD 
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4.5.1.3. Clinical study of Karuvilanchi ver chooranam in osteoarthritis 
Sl.No. O.P. No. Name Age/ Sex Date of first visit Symptoms Date of last visit Results 
21. 2756 YOGESHWARI 41/F 14.8.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕  8.11.2012 
 
FAIR 
22. 2974 ARPUTHAM 35/F 15.8.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 23.10.2012 GOOD 
23. 3529 KANNIGA 42/F 17.8.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 5.10.2012 FAIR 
24. 4309 MUSTHAPHA 54/M 21.8.2012 
Pain & swelling in left knee joint,  
morning stiffness ⊕ 19.10.2012 GOOD 
25. 5895 THILAGAM 50/F 28.8.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 12.10.2012 FAIR 
26. 5949 VALLIAMMA 65/F 28.8.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 8.11.2012 GOOD 
27. 7379 ANJALAI 55/F 4.9.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 12.10.2012 GOOD 
28. 7410 PUSHPA 46/F 4.9.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 5.11.2012 GOOD 
29. 7650 VENUGOPAL 50/M 5.9.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 8.11.2012 GOOD 
30. 8743 SELVAN 61/M 10.9.2012 
Pain & swelling in  both knee joints ,  
morning stiffness ⊕ 10.10.2012 GOOD 
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4.5.1.4. Clinical study of Karuvilanchi ver chooranam in osteoarthritis 
Sl.No. O.P. No. Name Age/ Sex Date of first visit Symptoms Date of last visit Results 
31. 9093 RAMALINGAM 60/M 11.9.2012 
Pain & swelling in right knee joint,  
morning stiffness ⊕ 28.10.2012 
 
GOOD 
32. 9945 KANAGA 45/F 14.9.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 24.10.2012 FAIR 
33. 9965 GOWRI 58/F 14.9.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 8.11.2012 GOOD 
34. 1457 VARADHAN 47/M 2.9.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 24.12.2012 GOOD 
35. 2645 RANGASAMY 65/M 26.9.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 5.11.2012 GOOD 
36. 3808 NAGHARANI 45/F 1.10.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 18.11.2012 GOOD 
37. 5646 NIRMALA 42/F 8.10.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 12.11.2012 GOOD 
38. 8037 KASTHURI 57/F 18.10.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 5.12.2012 GOOD 
39. 3081 BIROSE 35/F 17.11.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 9.12.2012 GOOD 
40. 3683 YASINBEEVI 60/F 17.11.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 30.12.2012 GOOD 
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4.5.1.5. Clinical study of Karuvilanchi ver chooranam in osteoarthritis 
Sl.No. I.P. No. Name Age/ Sex Date of first visit Symptoms Date of last visit Results 
1. 711 SIKANDAR BANU 52/F 18.6.2012 
Pain ⊕ in both knee  joints, 
morning stiffness ⊕ 1.7.2012 
 
FAIR 
2. 1055 MANI 55/M 18.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 1.8.2012 GOOD 
3. 1090 JEYAMARY 55/F 23.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 16.8.2012 GOOD 
4. 851 RANI RAMADAS 57/F 25.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 3.8.2012 GOOD 
5. 1136 KANNAN 62/M 28.7.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 17.9. 2012 FAIR 
6. 1232 TAMILSELVI 50/F 8.8.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 5.9.2012 GOOD 
7. 1338 MARY 43/F 24.8.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 8.9.2012 GOOD 
8. 1355  MARAGATHAM 55/F 26.8.2012 
Pain ⊕ in both knee  joints, 
morning stiffness ⊕ 29.9.2012 GOOD 
9. 78 VASUDEVAN 62/M 24.9.2012 
Pain & swelling in both knee joints,  
morning stiffness ⊕ 12.10.2012 GOOD 
10. 156 RAMAJEYAM 59/M 10.10.2012 
Pain ⊕ in both knee  joints, 
morning stiffness ⊕ 22.10.2012 FAIR 
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4.5.2.1. Haematological parameters of patients of osteoarthritis  
 
Sl. 
No. O.P. No. Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) 
Hb(Gm) BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT AT 
BT AT Alb Sug Dep Alb Sug Dep 
P L E P L E 
½ hr 1 
hr 
½ 
hr 
1hr 
1. 5852 KUMAR 45/M 8570 66 31 3 9500 50 46 4 - 70 20 45 9.8 10.6 NIL NIL NIL NIL NIL NIL 
2. 5807 VALLIAMMAL 55/F 9400 58 37 5 7800 62 34 4 40 88 10 20 10.4 13.7 +++ NIL 
4-5PC 
1-2EC NIL NIL OPC 
3. 8053 RAMADAS 60/M 10100 62 28 10 8700 61 34 5 4 10 4 10 12 13.8 NIL NIL OPC NIL NIL NIL 
4. 851 MISBARA 57/F 10600 64 32 4 8800 59 37 4 20 50 8 15 11.6 12.2 NIL NIL 10-12EC NIL NIL NIL 
5. 2698 MALLIGA 60/F 9700 58 35 7 9200 58 38 4 29 75 14 35 9.0 11.5 NIL NIL OEC NIL NIL NIL 
6. 2764 MANIKKAM 60/M 9700 60 34 6 9800 60 36 4 7 13 6 10 12.0 13.1 NIL NIL OPC NIL NIL OPC 
7. 3228 REVATHI 45/F 9200 58 36 6 8100 61 34 5 11 20 6 12 10.8 11.5 NIL NIL OEC NIL NIL NIL 
8. 4000  JAYASHREE 35/F 8100 55 38 7 8800 58 34 8 20 50 8 20 8.0 10.2 NIL NIL NIL NIL NIL NIL 
9. 4443 VIJAYALAKSHMI 45/F 9600 58 39 5 9900 60 35 5 20 45 8 18 11 12.2 NIL NIL NIL NIL NIL NIL 
10. 6290 BANUMATHI 59/F 8800 56 30 5 9700 69 27 4 25 52 7 18 9.8 12.1 NIL NIL NIL NIL NIL NIL 
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4.5.2.2. Haematological parameters of patients of osteoarthritis  
 
Sl. 
No. O.P. No. Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) 
Hb(Gm) BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT AT 
BT AT Alb Sug Dep Alb Sug Dep 
P L E P L E 
½ hr 1 
hr 
½ 
hr 
1hr 
11. 7545 ANANDAN 53/M 9800 59 36 5 9700 60 36 4 17 52 7 20 13 14.8 NIL NIL NIL NIL NIL NIL 
12. 7590 MOHAMMED EHIYA 61/M 10100 64 31 5 7600 52 40 8 7 25 6 21 12.4 13.8 NIL NIL NIL NIL NIL NIL 
13. 7656 SUBRAMANIUM 68/M 9000 57 36 7 9500 59 36 5 20 44 8 22 11.6 12.2 NIL NIL OPC NIL NIL NIL 
14. 8738 SHANTHI 48/F 9700 60 34 6 9200 62 34 4 50 85 10 18 10.2 11.3 NIL NIL OEC NIL NIL NIL 
15. 8830 SRINIVASAN 45/M 8700 62 31 7 8000 56 37 7 26 50 7 18 9.6 10.3 NIL NIL NIL NIL NIL NIL 
16. 8856 SAGHADEV1 43/F 9600 65 29 6 9200 64 32 4 26 42 8 17 10.6 11.4 NIL NIL NIL NIL NIL NIL 
17. 9197 RAGOTHAMAN 62/M 9200 62 35 3 9800 63 35 2 35 54 8 22 9.6 10.1 NIL NIL NIL NIL NIL NIL 
18. 125 SHANTHI 48/F 8,200 67 30 3 8500 56 38 5 26 58 7 20 10.8 13.2 NIL NIL NIL NIL NIL NIL 
19. 515 VIJAYALAKSHMI 45/F 9,600 64 32 4 9800 63 32 5 24 52 8 16 10.4 12.6 NIL NIL NIL NIL NIL NIL 
20. 528 KANCHANA 60/F 9000 56 39 5 9300 62 35 3 5 20 5 13 10 12.4 NIL NIL NIL NIL NIL NIL 
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4.5.2.3. Haematological parameters of patients of osteoarthritis  
 
Sl. 
No. O.P. No. Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) 
Hb(Gm) BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT AT 
BT AT Alb Sug Dep Alb Sug Dep 
P L E P L E 
½ hr 1 
hr 
½ 
hr 
1hr 
21. 2756 YOGESHWARI 41/F 9600 66 31 3 8500 52 44 4 24 70 20 45 9.8 12.1 NIL NIL NIL NIL NIL Opc 
22. 2974 ARPUTHAM 35/F 7000 65 31 4 7800 62 33 5 18 41 10 20 10.9 13.7 NIL NIL NIL NIL NIL NIL 
23. 3529 KANNIGA 42/F 8200 75 20 5 6300 51 44 5 25 70 18 40 9.7 10.2 NIL NIL    NIL NIL NIL NIL 
24. 4309 MUSTHAPHA 54/M 9700 54 41 5 7800 59 35 2 12 34 7 18 9.8 11.2 NIL NIL OPC NIL NIL NIL 
25. 5895 THILAGAM 50/F 9400 55 39 6 9600 58 38 4 20 43 12 35 10.8 11.5 NIL NIL OEC NIL NIL NIL 
26. 5949 VALLIAMMA 65/F 10,200 60 32 8 9800 62 34 4 22 54 9 22 10.0 12.2 NIL NIL OPC NIL NIL Opc 
27. 7379 ANJALAI 55/F 8400 52 43 5 9100 61 36 3 24 40 7 12 9.0 11.6 NIL NIL OPC NIL NIL NIL 
28. 7410 PUSHPA 46/F 9600 59 35 6 8600 58 36 6 20 46 12 20 10.8 12.2 NIL NIL NIL NIL NIL NIL 
29. 7650 VENUGOPAL 50/M 10,200 64 32 4 9900 62 33 5    14 30 8 18 13.8 15.2 NIL NIL NIL NIL NIL NIL 
30. 8743 SELVAN 61/M 9300 59 37 4 9700 65    31 4 4 12 4 8 15 16.4 NIL NIL NIL NIL NIL NIL 
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4.5.2.4. Haematological parameters of patients of osteoarthritis  
 
Sl. 
No. O.P. No. Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) 
Hb(Gm) BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT AT 
BT AT Alb Sug Dep Alb Sug Dep 
P L E P L E 
½ hr 1 
hr 
½ 
hr 
1hr 
31. 9093 RAMALINGAM 60/M 8800 58 36 6 8400 60 36 4 16 50 7 21 12 14.8 NIL NIL OPC NIL NIL NIL 
32. 9945 KANAGA 45/F 9000 55 39 6 8800 61 33 6 26 50 8   23  8 13.4 NIL NIL OEC NIL NIL NIL 
33. 9965 GOWRI 58/F 9600 59 35 6 9400 59 36 5 30 60 8 18 12.2 14.2 NIL NIL NIL NIL NIL NIL 
34. 1457 VARADHAN 47/M 9800 59 36 5 9300 60 36 4 16 40 8 18 12.2 14.6 NIL NIL OPC NIL NIL NIL 
35. 2645 RANGASAMY 65/M 9700 59 38 3 9200 56 36 8 14 30 7 19 12 13.6 NIL NIL NIL NIL NIL NIL 
36. 3808 NAGHARANI 45/F 9600 65 30 5 9700 65 31 4 25 48 7 18 10.2 11.4 NIL NIL NIL NIL NIL NIL 
37. 5646 NIRMALA 42/F 8200 60 35 5 9800 60 34 6 30 52 10 22 9.4 10.6 NIL NIL OEC NIL NIL NIL 
38. 8037 KASTHURI 57/F 10,700 60 36 4 8700 58 38 4 25 70 8 20 10.8 11.6 NIL NIL OEC NIL NIL NIL 
39. 3081 FIROZA 35/F 10,000 58 38 4 9800 65 30 5 18 32 7 18 10 11.6 NIL NIL NIL NIL NIL NIL 
40. 3683 YASINBEEVI 60/F 10,200 63 32 5 9600 62 35 3 30 62 5 18 11.4 12.6 NIL NIL NIL NIL NIL NIL 
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4.5.2.5. Haematological parameters of patients of osteoarthritis 
Sl. 
No. 
I.P. No. Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) Hb(Gm) BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT AT 
BT AT Alb Sug Dep Alb Sug Dep 
P L E P L E 
½ hr 1 
hr 
½ 
hr 
1hr 
1. 711 SIKANDAR 
BANU 
52/F 9600 65 31 4 8600 54 44 2 25 50 14 36 9.8 10.4 NIL NIL NIL NIL NIL Opc 
2. 1055 MANI 55/M 7200 64 32 4 7800 60 37 3 12 40 12 20 10.8 11.8 NIL NIL NIL NIL NIL NIL 
3. 1090 JEYAMARY 55/F 9200 75 20 5 8300 53 44 3 25 70 18 36 9.8 10.4 NIL NIL NIL NIL NIL NIL 
4. 851 RANI 
RAMADAS 
57/F 7400 68 26 6 7800 61 35 4 12 30 7 14 9.4 10.8 NIL NIL NIL NIL NIL NIL 
5. 1136 KANNAN 62/M 9700 54 31 7 9200 60 36 4 29 75 14 35 9.0 11.6 NIL NIL OEC NIL NIL NIL 
6. 1232 TAMILSELVI 50/F 10,000 61 34 5 9800 60 36 4 24 6 9 22 12.0 12.8 NIL NIL OPC NIL NIL Opc 
7. 1338 MARY 43/F 8300 66 30 4 8600 61 36 3 14 28 5 12 11.0 11.8 NIL NIL OPC NIL NIL NIL 
8. 1355 
 
MARAGATHA
M 
55/F 8100 55 38 7 8600 58 36 6 20 42 9 22 9.6 10.8 NIL NIL NIL NIL NIL NIL 
9. 78 VASUDEVAN 62/M 9800 57 39 4 9900 62 33 5 18 46 8 18 12 12.6 NIL NIL NIL NIL NIL NIL 
10. 156 RAMAJEYAM 59/M 9600 66 30 4 9500 65 31 4 25 52 14 35 9.8 10.8 NIL NIL NIL NIL NIL NIL 
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4.5.3 Algofunctional index before and after treatment with Karuvilanchi ver 
chooranam 
 
 
 
Sl.No OP/IP.No Name Age/ Sex 
Algo functional index 
Before treatment After Treatment 
1. 5852 Kumar 45/M 8 5 
2. 5807 Valliammal 55/F 9 4 
3. 8053 Ramadas 60/M 10 3 
4. 851 Misbara 57/F 9 3 
5. 2698 Malliga 60/F 10 2 
6. 2764 Manikkam 60/M 8 4 
7. 3228 Revathi 45/F 9 3 
8. 4000  Jayashree 35/F 8 2 
9. 4443 Vijayalakshmi 45/F 9 4 
10. 6290 Banumathi 59/F 9 2 
11. 7545 Anandan 53/M 8 5 
12. 7590 Mohammed ehiya 61/M 9 3 
13. 7656 Subramanium 68/M 8 2 
14. 8738 Shanthi 48/F 8 5 
15. 8830 Srinivasan 45/M 11 3 
16. 8856 Saghadev1 43/F 8 4 
17. 9197 Ragothaman 62/M 9 2 
18. 125 Shanthi 48/F 10 5 
19. 515 Vijayalakshmi 45/F 8 6 
20. 528 Kanchana 60/F 12 3 
21. 2756 Yogeshwari 41/F 10 4 
22. 2974 Arputham 35/F 9 5 
23. 3529 Kanniga 42/F 8 6 
24. 4309 Musthapha 54/M 8 5 
25. 5895 Thilagam 50/F 9 4
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4.5.4 Algofunctional index before and after treatment with Karuvilanchi ver 
chooranam 
 
Sl.no OP/IP.No Name Age/ Sex 
Algo functional index 
Before treatment After Treatment 
26. 5949 Valliamma 65/F 8 3 
27. 7379 Anjalai 55/F 9 2 
28. 7410 Pushpa 46/F 8 3 
29. 7650 Venugopal 50/M 8 4 
30 8743 Selvan 61/M 11 5 
31. 9093 Ramalingam 60/M 11 3 
32 9945 Kanaga 45/F 9 2 
33. 9965 Gowri 58/F 8 6 
34. 1457 Varadhan 47/M 8 2 
35. 2645 Rangasamy 65/M 10 3 
36. 3808 Nagharani 45/F 8 4
37. 5646 Nirmala 42/F 8 2 
38. 8037 Kasthuri 57/F 12 5 
39. 3081 Firoza 35/F 11 4 
40. 3683 Yasinbeevi 60/F 11 3 
41. 711 Sikandar banu 52/F 10 2 
42. 1055 Mani 55/M 9 4 
43. 1090 Jeyamary 55/F 9 2 
44. 851 Rani ramadas 57/F 9 5 
45. 1136 Kannan 62/M 8 2 
46. 1232 Tamilselvi 50/F 11 4 
47. 1338 Mary 43/F 9 3 
48. 1355  maragatham 55/F 9 2 
49. 78 Vasudevan 62/M 8 3 
50. 156 Ramajeyam 59/M 11 2 
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4.5.8. Statistical analysis 
Descriptive statistical analysis of algofunctional index in patients BT & AT 
Table. 4.5.8. A 
 
“p” value & statistical significance:  
Treatment Mean S.D S.E.M 
Before treatment 9.14 1.20 0.17 
After treatment 3.48 1.25 0.18 
       Table.A4.5.8 Showing Paired “t” test result. 
 From the table we calculated the descriptive statistic like Mean, S.D & S.E.M of 
Mean for the improvement score before and after treatment. 
 
 
 
“t” Table. 4.5.8 B 
t-Table S.D “t” Value “p” Value 
Pre vs Post 0.255 22.2024 <0.0001 
 
The two-tailed P value is less than 0.0001 
  By conventional criteria, this difference is considered to be extremely statistically 
significant.  
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5. RESULTS AND DISCUSSION 
 The word drug itself comes from the Swedish word “drug”, which means “dried 
plant”. Dried root powder of Smilax zeylanica (Karuvilanchi verchooranam) was taken 
for its anti inflammatory and analgesic activity.  
 Regarding the drug availability, this trial drug is available throughout the year for 
the treatment. Here, various studies have been carried out in this trial drug. The study 
includes literary collections, Pharmacognostic study, physico and Phytochemical 
analysis, toxicity study, pharmacological study, and clinical study. The drug has been 
selected for the treatment of Osteoarthritis in reference with Vathanithanam 800. 
 
4.2.1. Pharmacognostic aspect of Smilax zeylanica 
Anatomy of the root 
 
Diagnostic features 
Both thin and thick roots were studied. The thin root is 1.7mm in diameter (Fig 
4.2.1.1.1). It consists of epidermis, exodermis, cortex, pith and several vascular strands. 
The epidermis is single layered; the cells are brachy – sclereids; the cells are squarish in 
shape with very thick walls and narrow cell – lumen; the cell walls have dense, canal – 
like simple pits (Fig 4.2.1.2.1). Epidermal cells are 30µm thick. 
 
Inner to the epidermis is a single layer of darkly stained cell layer called 
exodermis. The cells of the exodermis are highly thick walled and lignified; the cell 
lumen is reduced to narrow area. (Fig .4.2.1.2.1). 
 
Ground tissue is differentiated into outer wide zone of sclerenchyma cells or 
fibres. The fibres are thick walled and lignified. The cell lumen is wide (Fig4.2.1.2; 
4.2.1.3.12). The central core is wide and forms the parenchymatous pith. (Fig.4.2.1.1.1). 
some of the pith cells are filled with dense tannin contents (fig 4.2.1.1.1, 4.2.1.2.1).  
 
The vascular system consists of radial vascular strands which are arranged in 
regular circle, there are about 27 xylem strands alternating with equal number of phloem 
strands. The xylem and phloem strands are embedded in the outer zone of sclerenchyma 
tissue. The xylem and phloem have exarch protoxylem and protophloem respectively. 
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Thick root:  
The thick root is 3.7mm in diameter. Its structure is basically similar to that of 
thin root, with minor differences. The outer epidermal cells of sclerotic layer is broken 
and reduced in thickness at several places in the thick root. (Fig.4.2.1.2.).The number of 
vascular strands is more in the thick root. The exodermal layer is thin. The xylem strands 
are in uniseriate radial rows and are larger than those of the thin root. The pith is 
disintegrated and the pith tissue is partly preserved. In the pith region there are wide 
circular canals or cavities ensheathed by one or two layers of thick walled cells. 
(Fig.4.2.1.1.). 
 
 
Structure of the vascular strands 
The xylem strands consist of one to three rows of angular, thin walled wide cells 
which are compactly grouped into spindle shaped segments (Fig4.2.1.2.1) In the thick 
root, the xylem segments consist of single radial row of tangentially elongate semi 
circular or rectangular cells (Fig4.2.1.2.2). The phloem strands are top shaped with 
exarch proto xylem point. They consist of wide, angular thin walled metaphloem cells; 
The cells become gradually narrow towards the protophloem end. (Fig.4.2.1.3.2) 
 
Crystals: 
In some of the pith cells are seen calcium oxalate crystals. The crystals are thin 
needles called raphides. Numerous needles are bundled together and occur in vertical 
position with in the cells. In transverse sections, the needles appear as closely aggregated 
circular bodies (Fig4.2.1. 3.3).  
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Fig.4.2.1.1.1 T.S of thin root –entire view 
 
Fig.4.2.1.1.2 T.S of thick root – half sector 
 
Ep - Epidermis 
Ex – Exodermis 
Pi - Pith 
 
Ph - Phloem 
Sc – Sclerenchyma 
Sec -Secretory cavity 
 
Ta - Tannin 
Tc – Tannin cell 
X – Xylem 
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Fig.4.2.1.2.1 T.S. of thin root – A sector enlarged showing radial alignment of 
exarch xylem and phloem 
Ep – Epidermis              Sc – Sclerenchyma   PX – Protoxylem  Mx – Metaxylem 
Ex – Exodermis             Ph – Phloem              Ta - Tannin 
Fig.4.2.1.2.2 T.S of thick root - a sector showing exarch xylem and phloem strands 
Mx – Metaxylem Ph – Phloem Ep – Epidermis Pi –Pith Sc – Sclerenchyma 
 PX - Protoxylem 
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Fig. 4.2.1.3.1 A single exarch xylem strand – Enlarged 
 
Sc – Sclerenchyma    Mx – Metaxylem PX - Protoxylem 
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                                 Fig.4.2.1.3.2 Exarch phloem strand – Enlarged 
 
Fi - Fissure 
MP - Metaphloem 
PP – Protophloem 
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Fig.4.2.1. 3.3 Raphide type of crystal seen in cross sectional view within pith 
parenchyma 
  
 
PC - Pithcell 
Ra - Raphides 
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4.2.2.1. PHYSICO-CHEMICAL ANALYSIS: 
 
S.No Parameter Mean Value 
1. Loss on Drying at 105°C 6.196 % 
2. Total Ash  3.373 % 
3. Acid insoluble Ash   1.025 % 
4. Water Soluble Extractive 4.6 % 
5. Alcohol Soluble Extractive 5.3 % 
6. Particle size Completely passes through sieve no.44 
7. pH 6.5 
 
 
 
TLC 
 
Fig 4.2.2.2 After spray with visualizing agent 
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4.2.2.2 TLC Rf value 
Sl.No 
 
After Dipping in Vanillin-Sulphuric acid 
 
Rf value 
Colour of the spot 
 
1 0.22 Purple 
2 0.31 Purple 
3 0.38 Purple 
4 0.44 Yellow 
5 0.47 Purple 
6 0.64 Brownish yellow 
7 0.69 Violet 
8 0.77 Yellow 
11 0.82 Purple 
12 0.98 Brown 
 
 
 
4.2.3. Qualitative phytochemical Analysis 
Table4.2. 3: Showing the phytochemical analysis of   Karuvilanchi ver chooranam 
 
Qualitative Phytochemical Tests 
1. Alkaloids + ve 
2. Anthraquinones  - ve 
3. Flavonoids + ve 
4. Triterpenes + ve 
5. Steroids + ve 
6. Phenol + ve 
7. Saponin + ve 
8. Tannin + ve 
9. Coumarin  - ve 
10. Cardiac glycosides - ve 
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The qualitative analyses of Karuvilanchi ver chooranam was carried out in both dry 
and wet samples. From the test results alkaloids, flavonoids, tannins, triterpenes, 
Steroids, Saponins, phenolic Compounds were revealed to be present, whereas Cardiac 
glycosides, anthroquinones, coumarin were reported to be absent.  (Table 3) 
• Flavonoids have anti oxidant activity along with tannins and phenols. 
• The presence of Steroids and flavanoids indicates the anti inflammatory and 
analgesic activity. 
It is these secondary metabolites which can have therapeutic actions in humans and 
which can be refined to produce drugs.  
4.2.2.3. SCANNING ELECTRON MICROSCOPE (SEM): 
 
Fig.4.2.2.3. SEM 
 
RESULTS:  
  SEM picture shows size of the sample is in Nano particle (Micro level).  
 The aims for nanoparticle entrapment of drugs are enhanced delivery to, or uptake 
by, target cells and/or a reduction in the toxicity of the free drug to non-target organs. 
These situations increase the therapeutic index, the margin between the doses resulting in 
a therapeutic efficacy but toxicity to other organs occur. So, creation of long-lived and 
target-specific nanoparticles is needed. 
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4.2.2.4 FTIR RESULTS: 
 
Fig.4.2.2.4 FTIR graph 
          
4.2.2.4 FTIR results 
 
Frequency bands Functional Group 
3410.3 Alcohol/Phenol O-H Stretch 
2922.0 Carboxylic Acid O-H Stretch 
2371.9 Phosphonates 
2345.7 Phosphonates 
2124.1 Alkynyl C=C Stretch 
1638.5  Aromatic C=C Bending 
1376.1 Alkyl –methyl 
1250.5 
 
Trifluromethyl 
fluoroalkanes 
1049.7 Fluoroalkanes 
ordinary  
608.1 Chloroalkanes  
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4.2.4. CHEMICAL ANALYSIS OF KARUVILANCHI VER CHOORANAM: 
RESULTS: 
The Chemical analysis of Karuvilanchi ver Chooranam showed the following chemicals, 
 
¾ Proteins  
¾ Starch 
¾ Alkaloids 
¾ Tannic acid 
¾ Iron  
 
4.3. TOXICITY STUDY 
Using acute toxicity study in mice the non-toxic effect of Karuvilanchi ver 
chooranam in mice was confirmed and the safety of the drug was ensured upto 5g/kg 
upon oral administration. Hence the therapeutic dose was finalized as 250 and 500mg/kg 
as per the standard reference.  
Table 4.3.1: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 1000 + - - + - + - - - - - - - - - - - - - - 
2. 2000 + - - + - + - - - - - - - - - - - - - - 
3. 5000 + - - + - + - - - - - - - - - - - - -  - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased 
Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. 
Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. 
Mortality 
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4.4. PHARMACOLOGICAL STUDY: 
4.4.1. ANTI INFLAMMATORY AND ANALGESIC ACTIVITY 
The result of the analgesic activity evaluated using hot plate method revealed that 
the reaction time for mice was significantly increased in a dose dependent manner after 
one hour of oral administration. The effect of Karuvilanchi ver chooranam on the 
writhing response in mice is shown in Table 4.4.2. It was found that both Karuvilanchi 
ver chooranam and Aspirin caused an inhibition on the writhing response induced by 
acetic acid. Doses of 250 and 500 mg/kg of the Karuvilanchi ver chooranam and aspirin 
respectively, could completely block the writhing response exhibited about 61.51 and 
72.51% inhibition. Acetic acid, which is used as an inducer for writhing syndrome, 
causes algesia by liberation of endogenous substances, which then excite the pain nerve 
endings. The Karuvilanchi ver chooranam was found to exert a significant inhibitory 
activity on writhing response in dose range of 500 mg/kg.  
 
 The results obtained rather suggest that Karuvilanchi ver chooranam posses an 
antinociceptive activity and the mode of action might involve a peripheral mechanism. 
However, the central mechanism also might be involved. Formalin induced hind paw 
oedema is the standard experimental model of acute inflammation. The antiinflammatory 
action of the drug Karuvilanchi ver chooranamwas found to be moderately effective in 
the animal model. In acute inflammation model, the formalin induced paw oedema was 
significantly reduced by all the doses used when compared to control (P<0.05). Pain and 
inflammation are essential prelude to repair process. The mechanism of antiinflammatory 
action of Karuvilanchi ver chooranam may be related with the inhibition of 
prostaglandin biosynthesis enzymes such as lipooxygenase and cyclooxygenase, 
increased vascular permeability and inhibition of degranulation of mast cells.  
 
 Hence, the drug used for the trial proved to be a better alternative for the 
commercially available allopathic drugs. The inhibitory effect of the standard drug 
aspirin at a dose of 100mg/kg showed an average reduction of 33.33%. The results of the 
present investigation suggest that Karuvilanchi ver chooranam have significant anti-
inflammatory effect against formalin induced paw oedema. Karuvilanchi ver chooranam 
indicated good pharmacological action and hence deserving detailed Investigation for 
other pharmacodynamic effects. 
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Table 4.4.1: Effect of Karuvilanchi ver chooranam on pain induced by hot plate 
method 
Treatment Dose Reaction 
time in 
sec. before 
drug 
% increase in reaction time after drug 
treatment 
30min 60min 120min 
Saline 3ml/kg 2.8±0.05 12.4±0.04 13.2±0.4 14.10±0.5 
Karuvilanchi 
ver 
chooranam 
250mg/kg 3.0±0.04 22.2±0.36** 28.23±1.12** 32.24±2.11** 
Karuvilanchi 
ver 
chooranam 
500mg/kg 2.8±0.05 36.1±0.40** 44.29±1.20** 47.02±2.24** 
Pentazocine 5mg/kg 3.1±0.14* 66.22±1.28** 68.17±2.00** 67.34±1.82** 
 
Values expressed in mean ±SEM and units in seconds, Significant *p<0.05, **P<0.01 
(n=6) 
 
Table 4.4.2 Effect of Karuvilanchi ver chooranam on writhing response in mice 
Experiment Number of writhes Inhibition (%) 
Control 38.2±7.3 ----- 
KVC 250 mg/kg 14.7±5.0* 61.51 
KVC 500 mg/kg 10.5±4.8** 72.51 
Aspirin 150 mg/kg 6.3±2.4** 83.50 
 
Values are expressed as Mean±S.E.M. Drug and test compounds were given orally 30 
min before 0.3% acetic acid injection. *P<0.05; significantly different from the control 
group (N=6). 
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Table 4.4.3 Effect of Karuvilanchi ver chooranam on formalin-induced edema in 
hind Paw of rats 
S.No Treatment Dose 
(mg/kg) 
Mean increase in 
paw volume 
Percentage inhibition
1. Control 5ml/kg 0.42±0.44 ---- 
2. Karuvilanchi ver 
chooranam 
250mg/kg 0.37±0.61* 11.90 
3. Karuvilanchi ver 
chooranam 
500mg/kg 0.35±0.62** 16.66 
4. Acetyl salicylic 
acid 
100mg/kg 0.28±0.64** 33.33 
Values expressed in mean ±SEM, Significant *P<0.05; **P<0.01 compared to control 
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6. CONCLUSION 
The trial drug “Karuvilanchi ver Chooranam” has been selected and its efficacy 
was analyzed in the treatment of Osteoarthritis. 
The plant is readily available and preparation is also simple. 
The trial drug is not only efficient, but also cost effective. 
The results of the present pharmacological study suggest that Karuvilanchi ver 
chooranam have significant anti-inflammatory effect against formalin induced paw 
oedema 
The drug shows good Anti inflammatory and analgesic activity. During the entire 
clinical trial no adverse effects resulted. 
From all the above observations, I conclude that the trial drug “Karuvilanchi ver 
chooranam” (Smilax zeylanica,) gives a new hope in the Osteoarthritis Treatment.  
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7. SUMMARY 
The herb Karuvilanchi ver was collected from Kanyakumari (Dt), Tamil Nadu 
and it is then purified, powered and stored. This drug was subjected to different studies 
by the author. 
“Karuvilanchi ver Chooranam” was selected for this dessertation study to 
evaluate the Anti inflammatory and analgesic activity, and also to prove its efficacy and 
safety in Osteoarthritis.  
The information about the drug, was collected from various text books, Literature 
were referred. From these informations, the author came to an idea about the drug and its 
efficacy on Osteoarthritis. 
A brief description about botanical aspect of the herb Karuvilanchi ver and its 
identifying characters and phytochemical analysis reports were given. 
The pharmacological analysis revealed that the drug has got significant Anti 
inflammatory and analgesic activity. 
In clinical study, the drug has showed remarkable improvement in 78% of cases. 
The patients responded well from the commencement of the treatment and there 
were no adverse effects during the course of the clinical trial. 
This present study suggests that Karuvilanchi ver Chooranam has the significant 
medicinal value against the disease osteoarthritis without any adverse effect. 
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1. INTRODUCTION 
 
“Science without religion is blind 
And religion without science is lame” 
- Albert Einstein 
 
Based on the ancient Tamil literatures, ‘Tholkappiyam and Silappathikaram’ the 
siddha system of medicine flourished in the first Tamil sangam period [sixth century 
B.C].In Tholkappiyam the siddhars were introduced as ‘arivar’ in the quotation, 
 
“kWtpy; nra;jp %tiff; fhyKk; 
newpapd; Mw;wpa mwptd; NjaKk;” 
- Tholkappiyam – purathinai iyal 74 
 
Ilampooranaar has written the meaning for the above said quotation as, 
“Fw;wkw;w nraiyAila kioAk; 
gdpAk; ntapYkhfpa %tiff; 
fhyj;jpidAk; newpapdhw; nghWj;j 
mwptd; gf;fKk;” 
 
  Siddhars were great doctors of medicine, philosophers, and men with deep 
knowledge of anatomy and chemistry noted for their wide travel, simple living and high 
thinking. They were the pioneers in the use of metals and minerals in the treatment of 
various diseases. 
 
In Siddha, diseases are diagnosed mainly with the help of signs and symptoms of 
the diseases. Other factors that also help to diagnose diseases are touch, examining the 
pulse, tongue, colour, speech, eyes, faeces and urine. The main aim of Siddha system of 
medicine is to assure a healthy life which includes both physical and mental health to 
man kind. A siddhar is one who has attained siddhi, i.e. "power, prowess, strength, 
ability", a special kind of psychic and supernatural, miraculous, occult power.  There are 
8 kinds of super natural powers called as "Ashtama Siddhis". The materials used by 
siddhars, as drugs could be classified into herbal products [thavaram], inorganic 
substances & navamanigal [thathu] and animal products [jangamam]. The thathu 
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products are further classified into logham, mercurial compounds, pashanam, karasaram 
and uparasaam.  
 
Diuretics are medicines that aid the elimination of sodium (salt) and water from 
the body. 
 
 A diuretic provides a means of forced diuresis which elevates the rate of 
urination. There are several categories of diuretics. All diuretics increase the excretion of 
water from bodies. When the kidneys excrete sodium, they excrete water from the blood 
along with it that decreases the amount of fluid flowing through the blood vessels, which 
reduces pressure on the walls of the arteries. 
 
In modern medicine, diuretics are used to treat heart failure, liver cirrhosis, 
hypertension and certain kidney diseases Up to one in three heart-failure patients who 
take diuretic drugs experience diuretic resistance: when the process of eliminating excess 
sodium and water stops before enough fluid has been removed from the patient's body. 
   
The main adverse effects of diuretics in modern medicine are hypovolemia, hypokalemia, 
hyperkalemia, hyponatremia, metabolic alkalosis, metabolic acidosis and hyperuricemia. 
So, there is a need for more effective and less toxic diuretic. 
 
“Chendooram” is a category of medicine with reddish colour and powdery form 
unlike in the ayurvedic system, where ‘sindoora’ cotain mercury and sulphur as a rule 
and involve heating to get a sublimate, 
 
The ‘chendooram’ in siddha system need not necessarily contain sulphur or 
mercury and there are instances where no heating is required at all in the processing. 
Thus, atleast 5 different modes of preparation of ‘chendooram’ are present.  
They are  
 1. ‘Chendooram’ prepared without heating. [araippu chendooram] 
 2. ‘Chendooram’ prepared by open heating [erippu or varuppu chendooram] 
 3. ‘Chendooram’ prepared by capsule heating [puda chendooram 
 4. ‘Chendooram’ prepared by sand bath process [ kuppi erippu chendooram] 
 5. ‘Chendooram’ prepared by applying heat in the range close to 100ºc [ laghu puda         
chendooram] 
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 Chendoorams are special medicine in siddha system and they are said to retain 
their potency for 75 years. The speciality of chendoorams can be understood by the 
books like ‘agathiyar chendooram 300’. 
 
  ‘Jala manjari chendooram’ is one of the erippu chendooram in siddha system 
which is written by the great siddhar yoogi muni in ‘Yoogi Karisal 151’ indicated for 
anemia, edema etc., the name Jalamanjari, ‘ jala’ means water, which itself indicates the 
diuretic action of the drug.  Although many herbs are available as diuretics, the use of 
jalamanjari chendooram is justified by the fact that the herbs are available only in 
seasons, but does not occur throughout the year. 
 
The trial drug ‘Jala manjari chendooram’ will be clinically given for the patients 
with urolithiasis, edema, ascites and hypertension as these diseases can be treated well 
with diuretics. 
 
  The shelf life period of this drug is very long it will be available throughout the 
year. So I am interested to scientifically validate this trial drug ‘Jalamanjari 
Chendooram’, 
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2. AIM AND OBJECTIVES 
 The Aim of the Study is to prove the efficacy of the ‘Jalamanjari chendooram’ 
for Diuretic activity. Diuretics are necessary for treatment in conditions like Oedema, 
Hypertension, and Renal calculus.  
 
Synthetic Diuretics such as Loop Diuretics [Frusemide] and Thiazide like 
Diuretics accomplish the demand but cannot be used for long term as they produce 
decrease in concentration of electrolytes which in turn results in serious conditions. 
Diuretics like loop diuretics, thiazides are synthetics in nature and they do not contain 
any active constituents, nutrients or any other medicinal or tonic properties to 
mankind. 
 
‘Jalamanjari chendooram’ is a drug which offers actions of elimination of excess 
body fluids as in oedema, ascites etc which is indicated in the literature.  
 
Hence the Aim of the Study is to prove the safety and efficacy of the 
‘Jalamanjari chendooram’ for Diuretic activity. 
 
Objectives 
      The objectives are 
 The drug was studied in the following aspects. 
1. Literature reviews. 
2. Chemical Analysis of ‘Jalamanjari chendooram’ 
3. Toxicity study. 
4. Pharmacological activity. 
• Diuretic activity. 
5. Clinical study. 
6. Statistical analysis of the results. 
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3. REVIEW OF LITERATURE 
 3.1. MATERIA MEDICA ASPECT  
Vennkaaram 
General Properties 
 
“nrhwpGilnaz; Fd;keik Nrhup ahrk; 
 gwpfpufzp fy;Y}dk; gd;Ndha; - newpiaj; 
 jlq;fzq;f gq;fpUkp ru;g;gtplQ; re;ep 
 aplq;fzq;f yf;fpw;Ngh nkz;.” 
Venkaaram is indicated for Toad skin, carbuncle, gastric ulcer, itching, 
haemorrhoids, hemiplegia, dental disease, urinary tract infections, kapha, veneral ulcer 
with pus, poison due to snake etc., delirium, infective disease, abdominal disease, cough,. 
It is also indicated for indigestion, rhinitis, delayed labour, amenorrhoea, dysmenorrhoea, 
hemorrhagia, sinusitis, stomatitis, ulcer on the nipple, anemia due to menorrhagia, 
epilepsy, uterus contraction in slow delivery. 
Uses 
• Roasted Borax (650mg – 1300mg) is given with tender coconut water for Urinary 
tract infections. 
•  Borax mixed with water may be used as an irritation solution for bladder wash in 
case of urethritis. 
• Borax 325mg – 975mg is given for Ascites. 
 
Ayam 
General Properties 
“ghz;Lntz; Fl;lk; gUe;J}y Neha;Nrhig 
khz;blr;nra; ke;jq;fh khiyFd;;kk; G+z;l 
ngUe;jhJ el;lKk;Nghk; Ngjpgrp Az;lhq; 
fUe;jhJ el;lkpLq; fhy;” 
Iron preparations are used in treating the disease like anemia, jaundice, leucoderma, 
obesity, dropsy, anorexia, peptic ulcer, spermatorrhoea, diarrhoea and dyspepsia. 
Uses 
• Aya parpam is indicated for 
¾ Ascites (peruvayiru) in adjuvant Piper longum oil or its rasam. 
¾ Anuria in adjuvant breast milk. 
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Kaantham 
General Properties 
“fhe;jj;jhw; NrhigFd;kq; fhkpyNk fk;ghz;L 
Nru;e;jjpup Njhlntl;il rPjq;fhy; - Xa;e;jgrp 
NgUjuq; fz;Nzha; gpukpaeP uhikAk;Nghk; 
Xupdpiw ahASWk; cd;” 
Kaantham is indicated for swelling, peptic ulcer, Jaundice, Gonorrhoea, Dropsy, 
Disorders of three humours, leucorrhoea, cold, Rheumatic disorders, Dyspepsia, 
Anasarca, Eye disease and spleenic tumor. It also increases the life span. 
Uses 
• Kaantha parpam with adjuvant  
¾ pure water is indicated for Vatha and associated illness such as 
Ascites, Abdominal Distension etc, 
¾ Garlic oil is indicated for kapha and associated illness such as 
Oliguria (Neerkattu). 
Ganthakam 
Nellikkai ganthakam  
(Gooseberry sulphur) 
“ney;ypf;fha; fe;jpf;F ePs;gjpndz;  Fl;lke;jk; 
ty;iy ftpirFd;k thAfz;Nzha; - nghy;yh 
tplf;fbtd; NkfNeha; tPWRuk; Ngjp 
jplf;fpuf zpfgk;Nghe; Nju;” 
 This is considered to be useful in the treatment of 18 types of skin diseases, liver 
enlargement, abdominal distension, eye diseases, chronic venereal diseases, 
chronic diarrhoeas, Gastric ulcer, poisonous bites, fever due to vatha, chronic 
dysentery etc. 
Vaana ganthakam 
(Stick sulphur) 
 This sulphur is useful to control the pathogenic micro organisms in the blood. It is 
also useful in the treatment of chronic joint disorders, scabies, asthma , heart 
attack, cough ,anorectal diseases, leprosy etc. 
Uses  
• Ganthaka parpam is indiated for ascites with adjuvant butter milk. 
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• Ganthaka chendooram prepared using the juice of Indian aloes in the dose 
of 130 – 260 mg will be useful in the treatment of abdominal distension 
etc. 
• Ganthaka rasayanam  
Dose: 1.3 to 1.9 gram 
¾ Is useful in the treatment of dysuria and swellings 
 
Navacharam 
General properties 
“Fd;;kk; Flw;#iy nfhy;Yk; kNfhjuj;ij 
td;ikAW fy;yilg;ig khw;Wq;fhz; - rd;kf; 
ftpr;RKj; Njhlq; fdthj ePf;Fk; 
etr;rhu khNj etpy;” 
Navacharam cures abdominal pain, distended abdomen, urinary calculus, bad 
odour in the skin, sinusitis, amenorrhoea, whooping cough, intermittent fever, three 
humours, indigestion, hepatomegaly, hepatitis, spleenomegaly, rhinitis, tuberculosis, 
haematemesis, and facial paralysis. 
Uses 
• The salt may be added to 500ml of boiled rice gruel and may be taken in little by 
little for treatment of leucorrhoea, blood disorder, chronic dysentery, bronchitis 
and disease of stomach and urinary bladder. 
• The salt dissolved in the decoction of Hygrophila auriculata may act as a diuretic 
and may be effective in the treatment of jaundice, liver enlargement and 
spleenomegaly. 
• Ammonium chloride is dissolved in water. A cloth is soaked in the solution and 
applied over the disease affected part. Its indications are swelling. Hepatitis, 
abdominal tumour, an inflammation of the lymphatic gland etc. 
Cheenakaram  
General properties 
“rPdnkDq; fhukJ rPwptU gy;yuiz 
Midf;fhy; fz;Nzha; mdpynkhL – khepyj;jpy; 
Jd;khq; fprk;thA Njhyhj cs;soiy  
Fd;;kkpit Nghf;Fnkdf; $W” 
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It cures gingivitis, eye diseases, Elephantiasis, Vayu, tumour, heat, gastric ulcer, 
hypertension, haemorrhage, Dysentry, diarrhoea, children’s vomitting, Whooping cough, 
cough with expectoration, pharyngitis, Menorrhagia and Gonorrhoea. 
 
 
Uses 
• Padikara Parpam : 
Dose: 130 – 520 mg  
Adjuvant: cow’s butter, juices of Aerva lanata (chiru peelai), Tribulus terrestris 
(chiru Nerunjil) 
Curable diseases: absolute suppression of urine, dysuria, stricture of urethra. 
 
Vediyuppu 
General properties 
“ky;yhWk; kl;lFd;;k khjUjuf; fl;b 
fy;yh kijg;GePu;f; fl;lUf – nyy;yhNk 
fk;gpfk;gp nad;Wq; fUTz;lh kq;fpepd;w 
fk;gpfk;gp nad;Wiuf;Fq; fhy;” 
The salt is useful in the treatment of 8 types of Gunmam, uterus fibroids, 
Anorexia, Urinary tract infections, dysuria, Stranguary, Ascites, Menopaused disorders, 
abdominal distension and Asthma. It improves fertility in women. 
Properties: 
Potassium Nitrate Salt has got  
• Demulcent  
• Diuretic & 
• Diaphoretic properties. 
 
Gomoothira silasathu 
General properties 
“Nfh%j; jpurpyh rj;jhw; FWfpNa 
Ngh%j; jpunkupTl; Gz;Nkfk; - ehNkT 
ntg;Gjpu ntg;GkWk; tPopKdp tpk;ge; 
Jg;GkQ;R nky;ypjoha; nrhy;” 
The asphaltum may be effective in burning micturition , ulcers of the urinary 
tract, Gonorrhoea, ulceration of the tongue and hypertension. 
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Uses 
• It is also effective in asthma, tuberculosis, diseases of the intestine, sterility, vatha 
disease, swellings and ulcers, urinary tract infections, dysmenrrhoea and 
rheumatism. This is also effective in rapid union of fractured bones. It removes 
calculus in the urinary and gall bladders. It is also useful in skin diseases. 
• For the abscesses developed due to kapha and pitha fevers, the gomoothira 
silasathu is given with the decoction of cotton seeds or coriander seeds for 4 to 5 
days. It may also be given for spleenomegaly. 
• The gomoothira silasathu (65mg) sticks prepared with wheat flour is inserted into 
the urethra for curing the urinary diseases. 
• For delirium and inflammation of the urethra, the gomoothira silasathu (65mg) is 
mixed with cow’s milk (raw) and given. 
 
Kalnar 
General properties 
“fhrgpj;jk; thjq; fLg;gPW NehnaupT 
tPRru;j;jp ePuilg;G tpe;Jel;lk; - NgRkir 
jpd;dhiu $Tke;je; jPf;Flu;f;fhy; jhfkpit 
fd;dhiuf; $ttpLq; fhz;” 
It is indicated for rheumatism, disease of teeth, gingivitis, urethritis, urinary 
retention, bilious vomiting, dysuria, spermatorrhoea, indigestion, hernia, thirst etc. 
Uses 
• Asbestos has got diuretic and bitter properties. 
• Kalnar parpam is taken along with ghee or butter at a dose of 260 – 520mg is 
effective in burning micturition, urinary retention and spermatorrhoea. 
 
Karpoora silasathu 
General properties 
“fy;yilg;G Nkfq; fdJ}yk; tpj;jpujp 
 nrhy;yilf;F ePuUfw; Nrhzpjf;fhd; - nky;ypilahu;f; 
 fpy;yfr;rj; jpy;iynaD kpe;jpupa el;lKkhq; 
 fy;yfr;rj; jpy;iynaDq; fhy;” 
Karpoora silasathu is useful in the treatment of vesicle calculus, gonorrhoea, and 
abscess with pus, strangury, articular rheumatism and spermatorrhoea. 
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Uses 
• Silasathu also cures gonorrhea, internal ulcers, hypertension, kapha disease, 
chronic cough and dysentery. 
• Karpoora silasathu parpam prepared using the juice of Molllugo lotoides  is 
given with cow’s  butter for burning sensation of the skin and dysuria. 
• Karpoora silasathu parpam prepared by adding borax is used for curing vesicle 
calculus in the urinary tract. 
Kavikkal 
General properties 
“mlyW ew;fhtpf;f yl;rpNeha; Nkfk; 
ntbaf;fp the;jp gpj;jk; tPl;Lk;” 
Kavikkal may be useful in the treatment of eye disease, venereal disease, 
vomiting and extensive eczema. 
Uses 
• Red ochre has got astringent taste and cool potency. It controls excessive 
bleeding – anti coagulant. 
• Poonkavi chendooram  
Dosage: 650 mg   
¾ With suitable adjuvants is used for the treatment of diarrhoea with 
bleeding, haemorragia and vomiting. 
Sangu 
General properties 
“frpth kpuj;j gpj;jq fz;Nzha;f NsFk; 
grpahWk; thjk; gwf;F- kprpTlNd 
jq;F Kistpuze; jhdfY Nknts;isr; 
rq;fkJ Tz;lhapew;whd;”  
It is useful in the treatment of hypertension, eye diseases, vatha diseases etc. 
Uses 
• The conch has body strengthening, deflatulant, and appetite stimulant, bitter and 
mucolytic properties. 
• Sangu parpam prepared using juice of Phyllanthus emblica is indicated for 
urinary tract infections. 
• Sangu parpam prepared using the whole plant juice of Tabenaemontana 
divaricata (Nanthiyavattam) is indicated for ascites in adjuvant honey 
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Table 3.1 Other diuretic preparations in siddha literatures 
Constituents Name of the drug Reference book 
• Vediyuppu 
• Venkaaram 
• Karpoora silasathu 
• Cheenakaram  
Vediyuppathi chunnam Anubogavaidya 
navaneedham part 3 
• Venkaaram 
• Karpoora silasathu 
• Kalnaar 
• Navacharam  
Venkaara parpam Anubogavaidya 
navaneedham part 3 
• Vediyuppu 
• Venkaaram 
• Kalnaar 
• Cheenakaram 
Cheenalavana parpam Kannusamyparambarai 
vaithiyam  
• Vediyuppu Neeradaippu neer Pulippani vaaithiyam 500 
• Vediyuppu 
• Cheenakaram 
• Navacharam               
Vediyuppu jeyaneer Anubogavaidya 
navaneedham part 3 
• Vediyuppu 
• Cheenakaram 
• Navacharam 
Padikara parpam Anubogavaidya 
navaneedham part 3 
• Vediyuppu 
• Ganthakam 
• Sangu  
Vediyuppathi chendooram Anubogavaidya 
navaneedham part 3 
• Vediyuppu 
• Ganthakam 
Villaiuppu  Anubogavaidya 
navaneedham part 3 
• Vediyuppu 
• Venkaaram 
Venkara chendooram Anubogavaidya 
navaneedham part 3 
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Constituents Name of the drug Reference book 
• Vediyuppu 
• Venkaaram 
Kara vediyuppu parpam Kannusamyparambarai 
vaithiyam 
• Vediyuppu 
• Navacharam 
Navachara kattu Anubogavaidya 
navaneedham part 3 
• Vediyuppu 
• Navacharam 
Vediyuppu chunnam Kannusamyparambarai 
vaithiyam 
• Karpoora silasathu Pavala silasathu parpam Kannusamyparambarai 
vaithiyam 
• Sangu  Vellai sangu parpam Kannusamyparambarai 
vaithiyam 
• Kalnaar 
 
Naattu kalnar parpam  Kannusamyparambarai 
vaithiyam 
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3.2. MODERN ASPECT 
Potassium Nitrate (Vediyuppu) 
 Potassium nitrate in solution is a refrigerant, efficient diuretic and diaphoretic, 
 It acts on the vascular system and thus reduces the frequency of the pulse. 
 Given in the solid form or in concentrated solution it acts as irritant. In weak 
solutions, it is an excellent refrigerant drink in fevers with hot and dry skin, 
parched tongue, with great thirst and scanty and high colored urine. 
 It is useful also in the early stages of dropsy, in cases of small pox, measles, 
influenza, catarrh, gonorrhea, and acute rheumatism, bleeding from the lungs, 
stomach, uterus or other internal organs attended by fever. 
 A mixture of nitre 2 parts and leaf juice of the Radish 1 part is given in doses of 
80 grains to relieve scalding and retention of urine, also suppression or scantiness 
of urine. 
 
    Asphaltum (Silasathu) 
 Source: 
Ejected out of rocks during hot weather in the lower Himalayas, Vindhya, and 
other mountain tracks and Nepal where iron abounds, naturally flowing out from 
between the fissures in the rocks; or it may be a tar formed in the earth from the 
decomposition of vegetable substances. 
 Silajit is of a bitter taste and of a smell resembling cow’s stale urine. This is 
known as   gomuthra silajit. 
 The other variety found in the bazaars is called Karpoora Silajit which occurs in 
white plates. 
 The black variety is the one mostly used in medicine after purifying it by certain 
processes.  
 Action:  
Locally, 
¾ Antiseptic 
¾ Anodyne 
¾ Parasiticide and 
¾ Antiphlogistic. 
           Internally, 
¾ Alterative 
¾ Tonic 
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¾ Slightly laxative 
¾ Cholagogue 
¾ Respiratory stimulant 
¾ Disinfectant 
¾ Expectorant 
¾ Intestinal antiseptic   
¾ Diuretic and 
¾ Lithontriptic 
         
Uses: 
• Charaka says “There is hardly any curable disease which cannot be 
controlled or cured with the aid of Silajit”. 
• It is specially employed in genito – urinary diseases and in diabetes; in 
gall stones, jaundice, enlarged spleen, fermentative dyspepsia, worms, 
digestive troubles, piles, adiposity, anasarca, renal stone, renal and bladder 
calculi, anuria etc., hysteria, neurasthenia, epilepsy and insanity nervous 
diseases; amenorrhoea, dysmenorrhoea and mennorrhagia; scrofula, 
tuberculosis, phthisis and leprosy; eczema , elephantiasis, anaemia, 
anorexia , biliary congestion, chronic bronchitis, asthma, fracture of bones 
etc.,  
• It is also useful in ascites, uraemia, cholaemia and the like. It is valuable 
in cases of diabetic albuminria, where both casts and albumin diminish; 
• The indigenous practitioners also used silajit as a diuretic and 
lithontriptic. 
• In the first stage  of ascites it is used with iron – rust together with milk 
diet; salt and water is stopped altogether. 
• In strangury or painful micturition Silajit is used with other diuretics and 
demulcents like the decoction of Tribulus terrestris, Glycyrrhiza glabra 
etc. 
• In albuminuria and chyluria it is beneficial with the decoction of 
astringents like catechu, Shorea robusta, juice of leaves of Cajanus 
indicus or of garlic. 
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Ferrum (Ayam) 
 
 Source: 
Rarely free in nature, though very widely distributed in both the organic and 
inorganic kingdoms. Found in nearly all rocks, soils, etc. variously combined 
with oxygen as haematite, magnetic iron ore etc., with sulphur as iron – pyrites; 
in the ashes of plants and even the blood of animals; also in the bile , chyle, 
gastric juice, lymph , milk , pigment of the eye and in the urine. 
 
 Action 
• Iron improves the quality of blood. Iron produces constipation and that is 
why it was recommended to be administered with Triphala powder. Iron 
stimulates the functional activity of all the organs of the body and is 
therefore a valuable general tonic. 
 
 Uses: 
• Iron and its preparations are generally given with selected vehicles. In 
consumption it is given with black pepper and long pepper. 
• In haemorrhagic diseases such as haemoptysis, haematuria, bleeding from 
piles etc., iron is commonly given with good results. 
• Iron is a valuable remedy in Bright’s disease and not cures the anaemia 
but also lessens the albumin. 
• Dr.H.C.Sen says “recent investigations have shown that iron in its mineral 
state is not absorbed. The only way in which it enters the system is as 
vegetable or mineral compound. 
• For chronic fever, anaemia, jaundice etc and urinary diseases as 
gonorrhea, strangury etc., a preparation called Mehamudgara rasa is 
recommended. 
• In diabetes and other urinary diseases, female complaints etc., pills called 
Virhat Somanatha rasa are recommended to be administered with honey. 
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Sulphur ( Ganthakam ) 
 Source: 
A non – metallic element found free in beds of gypsum and in a state of 
sublimation in regions of extinct volcanoes; also in combination with several ores 
called pyrites, as sulphates and sulphides of iron, copper, lead, zinc, mercury 
etc.,in India it occurs naturally in some parts, in Nepal, Kashmir, Afghanistan and 
in Burma. 
 
 Action: 
Sulphur is described as of bitter astringent taste with a peculiar strong smell. It 
increases bile, acts as a laxative and alterative and its preparations also act as 
alterative, laxative, diuretic and insecticide. Sulphur when taken internally and in 
small doses, becomes absorbed and may be detected in the sweat, milk and urine. 
It is a stimulant to the secreting organs such as the skin and the bronchial mucous 
membranes. It has a specific action on the rectum and increases the 
haemorrhoidal secretions. The sulphurous and mineral waters as they contain 
earthy and alkaline sulphates act as a laxative and diuretic, while the sulphurous 
acid disengaged from them acts as a diaphoretic. In large doses it acts as a 
purgative. 
 
 Uses: 
• In combination with mercury it is used in almost all diseases. It readily 
combines with and fixes metallic mercury and is therefore extensively 
used in combination with that metal. 
•  Sulphur is useful in cough, asthma, consumption and general debility; 
also in enlargement of the liver and spleen, chronic fevers etc. 
• For tympanitis, colic, ascites etc., a drastic purgative named Mahanarcha 
rasa is given with cold water. 
Sodii Biboras ( Venkaaram) 
 Source: 
It occurs as a natural deposit. Crude borax is found  in masses by evaporation of 
water, on shores of dried up lakes in India and Tibet; it is also obtained from 
themud of lakes surrounded by hills in Nepal. When purified by dissolving it in 
water, straining through cloth, evaporating to dryness and crystallizing, it is called 
borax. 
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 Action: 
¾ Diuretic 
¾ Emmenagogue 
¾ Astringent  
¾ Antacid and 
¾ Local sedative 
¾ Antiseptic 
 
 Uses: 
• Borax is given internally in doses varying from 10 to 30 grains, in acidity 
of the stomach, amenorrhoea, dysmenorrhoea, menorrhagia, puerperal 
convulsions and to promote uterine pains during labour. 
• As a solvent it is given in uric acid diathesis with good results. Dose is 
from 20 to 40 grains for an adult. 
• In small doses it is given to children as a laxative. It is also used in loss of 
appetite; painful dyspepsia, cough, asthma and diarrhoea.  
 
Alumen ( Padikaram) 
 Source: 
Chiefly found with peroxide of iron in Silajit or in Alum earths of Nepal or 
prepared from the alum shales in the Punjab, Rajputana, Bihar and Cutch States. 
As found in the bazaars, it is often mixed with impurities; it may be rendered fit 
for medicinal purposes by dissolving it in boiling water, straining the solution and 
evaporating it so as to obtain crystals, which should be preserved for use. 
 
 Action: 
¾ Astringent 
¾ Caustic 
¾ Haemostatic 
¾ Antispasmodic and  
¾ Antiseptic; 
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 Uses: 
• It is useful in leucorrhoea, haematuria, haemoptysis, menorrhagia, gastric 
and intestinal catarrh and other haemorrhages; 
• In narcotic poisoning in children it is a good and efficient antidote. 
• In haemorrhages from kidneys, uterus and other internal organs alum in 
doses of 10 to 12 grains thrice daily with or without opium is given with 
benefit, but not when much fever is present.  
• Alum lotion internally is administered to check haemorrhage from lungs, 
stomach, kidneys and other organs or to arrest excessive menstrual flow. 
Ammonium Chloride (Navacharam) 
 As obtained in the bazaars is generally very impure in dirty white or brownish 
transclucent cakes, “as it is manufactured from a kind of clay found at Karnal in 
the Punjab” – ( Chopra) 
 It is obtained by the combustion of excretions of various animals or of animal 
matters or by burning coals or common salt. It is a secondary product in the 
manufacture of coal gas. 
 It is generally obtained in India from unburnt extremities of brick kilns in which 
manure of animals, especially camel’s dung is used as fuel. To this coal and 
common salt are added and sublimed. It is thus obtained in white granular crystals 
or transparent masses. It is readily soluble in water and is highly deliquescent. It 
has a saline, disaggreable, nauseous and pungent taste. 
 
 Action: 
 
¾ Alterative 
¾ Expectorant and  
¾ Cholagogue in small doses. 
¾ Purgative in large doses. 
 
 Uses: 
• In urinary diseases chiefly where the urine is full of lithates it is very 
useful. 
• As an alterative it acts by slowly modifying the nutrition of the tissues ; it 
is a useful agent in chronic inflammatory diseases of the glands such as 
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thyroid , liver and spleenand in induration of the uterus, ovaries and the 
prostate. 
   
Silicate of Aluminia, Magnesia & Oxide of Iron (Kavikkal) 
 It is a calcerous mineral often made into small cakes and stamped with certain 
impressions. 
 It occurs in powder or irregular pieces of reddish brown or variegated colours. It 
is soft and somewhat and heavy. 
 Action: 
¾ Refrigerant 
¾ Astringent 
¾ Absorbent and 
¾ Antiseptic 
 
Uses: 
• Dose is 5 to 30 grains. Internally the powder with cream is given in advance cases 
of dysentery. 
• A paste made of it 2 parts, alum 4 and rose water 10 parts is given internally for 
scalding in the urine. 
• Externally a paste of it is applied to inflamed and swollen glands, also to ulcers 
and raw surfaces. 
  
Calcium 
 (Eng: lime) 
Lime is obtained from conch shells (Sangu) 
Uses: 
• Lime is used internally in dyspepsia, enlarged spleen and other 
enlargements in the abdomen and externally as a caustic. 
• As a caustic, lime is used as an application to enlarged glands and 
tumours. 
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Adjuvant: 
Honey 
Actions: 
¾  Demulcent   
¾  Laxative 
¾  Astringent        
¾  Antiseptic 
¾  Expectorant     
¾  Digestive 
¾  Stomachic     
¾  Sedative 
Characters: 
“IapUk yPistpf;f yf;fpg;Gz; ntg;Gly;Neha; 
iga nthopAk; grpAKWk;- itafj;jp 
nyz;Zkpir ahkUe;jpw; Nfw;w tDghd 
 ez;Zkiyj; Njndhd;wp dhy;”.  
- Pathartha guna sinthamani. 
• Honey is a good adjuvant and also cures kabam, cough,etc. 
• The honey has not only adjuvant action but also balances the three humors and 
maintains the good health condition of the body. 
“mDghd kha;g;gpd; mtpo;jKkha;j; Njhd;wp 
 fdkhd Njfepiy fhl;bg;- gpDNk 
 aurd; Kjy;Nth iuAkhl;L tpj;jhNy 
 gpurj; jpdhw;Nghk; gpzp”.           
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3.3 SIDDHA ASPECT OF THE DISEASE 
Siddha aspect of the disease: 
Kalladaippu: 
Synonym: Achmari 
Definition: 
      This disease is characterized by intermittent cessation of urine during micturition, 
pain at the tip of the penis, burning micturition, backache and small pebbles found in the 
urine. 
Aetiology:  
¾ Drinking of stagnant water 
¾ Carbohydrate diet 
¾ Excess intake of vadha food 
Classification: 
          It is classified into 4 types.They are 
¾ Vadha kalladaippu 
¾ Pitha kalladaippu 
¾ Kapha kalladaippu 
¾ Mukkutra kalladaippu 
General symptoms: 
¾ Frequency of urination 
¾ Intermittent cessation of urine 
¾ Pricking pain in penis 
¾ Inflammation of penis 
¾ Irritation of bladder and lower abdomen 
¾ Haematuria 
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Oothal noi: 
Synonyms: 
            Thommai noi, Sokai noi, Sobai noi. 
Definition: 
         This disease is characterized by anaemia and pallor, also the upper and lower 
extremities, face and abdomen distends against normal. This is called as ‘oothal’ disease. 
Since the patient feels so grievance, this is called as ‘sogai’. Since anasarca is present, 
this disease is called ‘veekam’. 
 
 
Aetiology: 
    “ghq;fhd rd;dpgh jr;Ruq;fs; 
       gfh;rpj;jg; gpuikrd;dp gutyhYk; 
    Njq;fhq;d gd;dhe; jPz;l yhYk; 
        rpy;tplq;fs; Njfj;jp Yhw yhYk; 
    Mq;fhd rpiwapUj;j ybgLj yhYk;  
        mNef top elf;fif kiy apUf;if ahYe; 
    jhq;fhd ryf;fiufs; jdyp ypUj;jy; 
        rhk;gy;kz; khjtplha; Nrhig ahNk.” 
 
¾ Follows anemia 
¾ Toxicosis 
¾ Food variants 
¾ Dysfunctioning of paravukaal 
¾ Sittha pramai sanni 
¾ Snake bite 
¾ Hilly residence 
¾ Damp and marshy areas 
¾ Pick’s disease 
Pre monitory symptoms: 
¾ Emaciation 
¾ Oedema 
¾ Exhaustion 
¾ Dyspnoea 
¾ Headache 
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¾ Fainting 
¾ Oedema of lower extremities, face and abdomen 
Classification: 
          This is classified into 4 types. They are 
¾ Vadha oothal noi 
¾ Pitha oothal noi 
¾ Kapha oothal noi 
¾ Mukktra oothal noi 
 
 
General symptoms: 
          “Nrhifap dpyf;fzq;Nfs; 
          Nrhh;T iffhy; fl;Fz;lhk;” 
 
¾ Anorexia 
¾ Exhaustion 
¾ Hydrocele 
¾ Thickness of the ear pinna 
¾ Hearing impairment 
¾ Squint 
¾ Pallor 
¾ Dyspnoea 
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3.4. MODERN ASPECT OF THE DISEASE. 
Diuresis:  
Diuresis means increased excretion of urine. 
Diuretics 
Diuretics are an indispensable group of therapeutic agents that are used to adjust 
the volume and /or composition of body fluids in a variety of clinical situations including 
hypertension, acute and chronic heart failure, acute and chronic renal failure, nephritic 
syndrome and cirrhosis. 
The word "diuretic" comes from Greek word ‘dia-‘=thoroughly + ‘ourein’ =to 
urinate so diuretic means to urinate thoroughly. 
Table 3.4.1 Classification of diuretics 
1. High efficacy diuretics (lnhibitors of 
Na-K- 2Cl- cotransport) 
 
- Sulfamoyl derivatives 
 
Furosemide, Bumetanide, Torasemide 
 
2. Medium efficacy diuretics (lnhibitors 
of Na-Cl- symport) 
(A) Benzothiadiazines (thiazides) 
 
 
Hydrochlorothiazide, 
Benzthiazide, Hydroflumethiazide, 
Clopamide 
 
 (B) Thiazide like (related heterocyclics) Chlorthalidone, Metolazone, 
Xipamide, Indapamide. 
 
3. Weak or adjunctive diuretics 
(a) Carbonic anhydrase inhibitors 
 
Acetazolamide 
(b) Potassium sparing diuretics 
 
i) Aldosterone antagonist: Spironolactone  
 
 
(ii) Inhibitors of renal epithelial Na+ 
channel: Triamterene, Amiloride. 
 
(c) Osmotic diuretics Mannitol, Isosorbide, Glycerol 
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Mechanism and uses of diuretics 
High ceiling diuretics 
 inhibit the Na-K-2Cl symporter 
 Uses 
 Edema – cardiac, hepatic or renal 
 Acute pulmonary edema 
 Cerebral edema 
 Hypertension 
 Hypercalcemia and renal calcium stones 
Thiazides 
 inhibit reabsorption by Na+/Cl- symporter 
 Uses 
 Edema 
 Hypertension 
 Diabetes insipidus 
 Hypercalciuria 
Carbonic anhydrase inhibitors 
 inhibit H+ secretion, resultant promotion of Na+ and K+ excretion 
 Uses 
 Glaucoma 
 Epilepsy 
 Acute mountain sickness 
 Periodic paralysis 
Potassium-sparing diuretics 
 inhibition of Na+/K+ exchanger: 
 Uses 
 Edema : cirrhotic and nephritic edema 
 To counteract K+ loss due to thiazide and loop diuretics. 
Osmotic diuretics 
 promote osmotic diuresis 
 Uses 
 Increased intracranial or intraocular tension. 
 To maintain g.f.r and urine flow in impending acute renal failure. 
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Oedema: 
Definition: 
The term oedema signifies increased fluid in the interstitial tissue spaces. 
Anasarca is a severe and generalized oedema with profound subcutaneous tissue 
swelling. 
 
Pathophysiologic categories of oedema 
 Increased hydrostatic pressure 
 Reduced plasma oncotic pressure  
 Lymphatic obstruction 
 Sodium retention 
 Inflammation.  
 Local increases in hydrostatic pressure may result from impaired venous outflow. 
For eg. Deep venous thrombosis in the lower extremities leads to oedema, which 
is restricted to the affected leg. 
 Reduced plasma oncotic pressure  can result  from excessive loss or reduced 
synthesis of albumin, the serum protein responsible for maintaining osmotic 
pressure. 
 Lymphatic obstruction: impaired lymphatic drainage and consequent 
lymphedema is usually localized. It results from inflammatory or neoplastic 
obstruction. 
 Sodium and water retention are contributory factors in several forms of oedema; 
 Salt retention may also be a primary cause of  oedema 
Table 3.4.2 Aetiology and types of oedema 
Generalised oedema Localised oedema 
1. Cardiac oedema 
2. Renal oedema 
3. Hepatic oedema 
4. Nutritional oedema 
5. Cyclic- premenstrual 
6. Idiopathic 
1.Venous oedema 
2. Lymphatic oedema 
3.Inflammatory oedema 
4.Allergic 
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Investigations 
The cause of oedema is usually apparent from the history and examination of the 
cardiovascular system and abdomen, combined with testing the urine for protein and 
measuring the serum albumin level. 
Liver function test 
Renal function test 
Complete haemogram 
Serum electrolytes 
Ultrasonogram of abdomen can also be done. 
 
Hypertension 
Definition 
Systemic hypertension is the persistent rise of basal blood pressure above the 
arbitrary level of 140/90 mm of Hg recorded on 3 or more successive occasions. There 
may be only systolic hypertension. In such cases systolic BP becomes 140 mm of Hg or 
above. 
Classification of Hypertension 
• Essential  or Idiopathic hypertension  
   Here no obvious cause is found to account for high blood pressure (90%-
95% of cases) 
• Secondary or Symptomatic hypertension 
    (5% -10% of cases) 
1. Renal causes (common): Acute nephritic syndrome, chronic nephritis, 
renal artery stenosis, renal embolism 
2. Endocrine causes: Thyrotoxicosis and myxodema, acromegaly, Cushing 
syndrome. 
3. Metabolic causes: Diabetes mellitus, chronic gout, Atherosclerosis. 
4. Drugs: steroids, contraceptive pills. 
5. Congenital: Coarctation of aorta 
6. Psychogenic 
7. Neurological: Encephalitis, Brain tumour, cerebrovascular accidents. 
8. Blood diseases: Polycythaemia 
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Essential hypertension 
Aetiology 
 Genetic factor: 
  Homozygos is usually seen to be severely affected than the heterozygous. 
 Sex: 
  Commonly seen in males. 
 Salt intake: 
    Excessive salt intake with genetic predisposition is very important. 
 Structural changes in arterioles: 
    Thickening of arteriolar wall and narrowing of the lumen lead to 
resistance in the blood flow.  
Clinical Features   
1.  Pulsating headache often occipital and occurs particularly in morning. 
2.  Easy fatigability   
3.   Dizziness  
4.   Insomnia 
5.   Lack of concentration 
6.   Loss of memory 
7.  Occasional palpitation 
8.   Breathlessness 
Symptoms of associated diseases may be present. 
• Cerebral Arteriosclerosis 
May give rise to 
   1. Hypertensive encephalopathy 
   2. Cerebral and subarachnoid haemorrhage 
   3. TIA 
   4. Convulsive Seizure  
• Renal Arteriosclerosis 
May give rise to 
1.Uraemia  
2.Haematuria  
3.Polyuria 
4.Nocturia 
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• CoronaryArteriosclerosis 
May give rise to 
1. Acute left ventricular failure 
2. Angina pectoris 
      3. Coronary thrombosis 
 
 
Urolithiasis 
Urolithiasis is the process of forming stones in the kidney, bladder, and/or ureters 
(urinary tract).  
Types of renal stones 
Renal stones can be broadly classified into radiopaque and radiolucent stones.  
 The commonest radiolucent stone is uric acid stone.   
  Less common radiolucent stones include xanthine and hypoxanthine stones.  
 Radiopaque stones constitute the majority of renal stones. All calcium stones are 
radiopaque. 
Etiological classification of urolithiasis 
I. Hypercalcemic  states 
II. Uric acid lithiasis 
III. Idiopathic renal lithiasis 
IV. Renal tubular syndrome and enzyme abnormalities 
V. Drugs   
i. Triametrene 
ii. Acyclovir 
iii. Indinavir 
iv. Sulphonamides 
Secondary nephrolithiasis 
1. Cystic renal diseases 
2. Urinary diversion procedures 
3. Stents, suture materials 
4. Catheters  
Clinical features 
• Colicky pain often associated with macroscopic or microscopic 
hematuria. 
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• The pain due to stone in renal pelvis is often abrupt in onset, 
intense in severity, intermittent and radiates from groin to loin. 
• The colic due to mid -ureteric stone is characterized by radiation to 
testes or labia. 
• Bladder stone are usually associated with frequency, strangury, 
urgency or dysuria. 
• General symptoms like sweating, nausea, and increased frequency 
also occur. 
• Anuria may occur when the obstruction is bilateral and complete 
or if the urethra is totally blocked. 
 
Table 3.4.3 Investigations of urolithiasis 
Sample Test 
Stone Chemical composition- most valuable when possible 
Blood 
 Calcium 
 Phosphate 
 Uric acid 
 Urea and electrolytes 
 Parathyroid hormone 
Urine 
Dip stick test for 
 Protein 
 Glucose 
 Amino acids 
24- hour urine 
 Urea 
 Creatinine clearance 
 Sodium 
 Calcium 
 Oxalate 
 Uric acid 
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4. MATERIALS AND METHODS 
4.1. PREPARATION OF JALAMANJARI CHENDOORAM 
ghz;L, kNfhjuk;, tPf;fk;, ePHf;fl;L ,tw;wpw;F 
       rykQ;rup rpe;J}uk; 
rykQ;rup KiwNfs; rz;ilntb ehd;Fgyk; 
fy;ehH kjQ;rj;J fhe;jkak; - ey;nfe;jp 
fhuQ;rPdQ; rhuk; fw;fhtp rq;Fnghb 
ghHtpuil apuz;L ghu;. 
 
ghu;nghb AUf;Fg; ghfkjpy; fl;btpl;Lr; 
rhu;ghapQ;rp Njd;nty;ye; jdpw;fhR – Neupilaha;j; 
jhf;F ,UNeue; jq;fhJ ghz;LtHf;fk; 
tPf;fKe; jPUk; tpUk;G.  
 
Purification methods: 
 Ayam: 
      The iron fillings were boiled for half an hour in both sesame oil and Piper 
beetle juice respectively to get it purified. 
 Gandhakam: 
Sulphur is melted in a spoon with butter; it was then poured into cow’s milk. 
The process was repeated for a total of 30 times washed in water and then dried. 
 Gomoothira silasathu : 
The asphaltum was ground with cow’s milk for the whole day and dried. 
 Kaantham: 
      It was grinded with lemon juice for 45 minutes to get it purified. 
 Kaavikkal: 
     It was soaked and grinded with tender coconut water, the mass was squeezed 
in a cloth and it was collected, and then dried in sun to get it purified. 
 
 Kalnaar: 
              The broken pieces of Kalnaar were soaked in cow’s urine for 10 days, 
       The urine was changed daily. It was then washed with water and dried. 
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 Karpoora silasathu: 
The impure form of silasathu is soaked in tender coconut water, boiled till 
it evaporates and washed to get it purified. 
 Navacharam: 
          It was dissolved in cow’s urine, filtered heated and then dried in sun and 
used. 
 Padikaram: 
The lumps were dissolved in pure water, filtered and boiled in a pan, when it 
attains thicky molten consistency, it was allowed to cool and the crystals that 
crystallize out were collected. 
 Sangu: 
To equal quantities of burnt lime stone and alkaline earth salt, 8 times of 
water, was added, stirred & the clear filtrate was decanted. In this solution, the conch 
shells were boiled from which the embedded sandy portions were removed, washed 
well and dried. 
 Vediyuppu: 
The salt was dissolved in 4 times of water and boiled, at the time of boiling, 
the white of hen’s egg was added dust separatedout and was removed. At a suitable 
consistency, the solution is transferred to a wide vessel, mouth of which is covered 
with a cloth and allowed to remain in a room where there are no wind disturbances. 
The crystals that were separated was again subjected to the above processes 7 more 
times and used. 
 Venkaaram: 
   Venkaaram is heated on a pan till it complete dehydrates 
 
Ingredients 
1. Purified Iron Filings – Suththi Seitha Ayapodi 70gms 
2. Purified Sulphur – Suththi Seitha Ganthakam 70gms 
3. Purified Asphaltum – Suthi Seitha Gomoothira Silasathu 70gms 
4. Purified Magnetic oxide of iron – Suththi Seitha Kaantham 70gms 
5. Purified Red ochre – Suththi Seitha Kaavikkal 70gms 
6. Purified Asbestos – Suththi Seitha Kalnaar 70gms 
7. Purified crystallised foliated Gypsum – Suththi Seitha Karpoora Silasaththu 70gms 
8. Purified ammonium chloride – Suthi Seitha Navacharam 70 gms 
9. Purified Alum– Suththi Seitha Padikaram 70gms 
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10. Purified conch shells – Suththi seitha sangu 70gms 
11. Borax, Dehydrated – Poriththa Venkaram 70gms 
12. Purified Salt Petre – Suthi Seitha Vediyuppu 140gms 
 
Method of preparation 
The purified drugs were powdered separately. The powders were mixed and 
grinded again into a very fine powder. 
A shallow container was heated and some amount of the powder was sprinkled in 
to it. The mixture first melted and then solidified. The solid was taken and allowed to 
cool. Similarly all the powders were used and the solidified products obtained were 
grinded into a very fine powder.  
Indications 
• Oedema, 
• Anaemia,  
• Swellings,  
• Ascites,  
• Suppression or retention of urine. 
 
 
 
 
Fig 4.1.1 Jalamanjari chendooram 
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Purified ingredients of Jalamanjari Chendooram 
 
             Fig 4.1.2 Purified vediyuppu 
 
 
        Fig 4.1.3     Purified kalnaar 
 
    Fig 4.1.4 Purified gomoothira silasathu 
 
Fig 4.1.6     Purified Kaantham 
 
      Fig 4.1.5    Purified  Karpoora Silasathu 
 
Fig 4.1.7     Purified Ayam 
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 Purified ingredients of Jalamanjari Chendooram 
  
 
       Fig 4.1.8    Purified Ganthakam 
 
                Fig 4.1.9  Purified Venkaaram 
         Fig 4.1.10 Purified Padikaram 
 
       Fig 4.1.11      Purified Navachaaram 
 
        Fig 4.1.12    Purified Kaavikkal 
 
    Fig 4.1.13      Purified Sangu 
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4. 2 STANDARDIZATION OF DRUG 
4.2.1.1 PHYSICO-CHEMICAL ANALYSIS: 
Procedures: 
Total ash  
Two grams of grounded air-dried material was accurately weighed in a previously 
ignited and tared silica crucible. The drug was gradually ignited by raising the 
temperature to 450°C until it was white. The sample was cooled in a desiccator and 
weighed. The percentage of total ash was calculated with reference to air-dried drug. 
Acid Insoluble ash  
The ash was boiled with 25 ml of 2 M hydrochloric acid for 5 minutes, the 
insoluble matter was collected on an ash less filter paper, washed with hot water, ignited, 
cooled in a desiccator, and weighed. The percentage of acid insoluble ash was calculated 
with reference to the air-dried drug. 
Water Soluble ash  
The ash was boiled with 25 ml of water for 5 minutes, the insoluble matter on ash 
less filter paper collected, washed with hot water, ignited, cooled in a desiccator, and 
weighed. The weight of the insoluble matter from the weight of the total ash was 
subtracted; the difference represents the water soluble ash. The percentage of water 
insoluble ash was calculated with reference to the air-dried drug. 
 
Determination of loss on drying 
. The sample was dried in an oven at 100oC -105oC until two consecutive weighing did 
not differ by more than 5 mg.  
. 
Potential of Hydrogen (pH): 
 The pH scale is logarithmic and runs from 0.0 to 14.0 with 7.0 being neutral. 
Readings less than 7.0 indicate acidic solutions, while higher readings indicate alkaline 
or base solutions. 
 
4.2.1.2 FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR) 
Instrument Details: 
Model   :  Spectrum one: FT-IR Spectrometer                                   
Scan Range   :  MIR 450-4000 cm-1                                                          
Resolution   :  1.0 cm-1                                                                                 
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Sample required :  50 mg, solid or liquid.                                           
Fourier Transform Infrared Spectroscopy (FTIR) is an analytical technique used to 
identify mainly organic materials. FTIR analysis results in absorption spectra which 
provide information about the chemical bonds and molecular structure of a material. The 
FTIR spectrum is equivalent to the "fingerprint" of the material and can be compared 
with cataloged FTIR spectra to identify the material. 
Fourier transform infrared spectroscopy analytical capabilities: 
• Identifies chemical bond functional groups by the absorption of infrared radiation 
which excites vibrational modes in the bond 
• Especially capable of identifying the chemical bonds of organic materials  
• Detects and identifies organic contaminants  
• Identifies water, phosphates, sulphates, nitrates, nitrites, and ammonium ions  
• Detection limits vary greatly, but are sometimes <1013 bonds/cm3 or sometimes 
sub monolayer  
• Useful with solids, liquids, or gases  
To confirm the acid and basic radicals of the trial drug to ensure the inorganic 
constituents 
 
 
4.2.1.3. SCANNING ELECTRON MICROSCOPE (SEM): 
The Scanning Electron Microscope (SEM) is a microscope that was electrons 
rather than light to form an image. There are many advantages in using the SEM instead 
of a light microscope. 
Resolution : 1.2 nm gold particle separation on a carbon substrate 
Magnification : From a min of 12 X to greater than 1, 00,000 X 
The SEM has a large depth of field, which allows a large amount of the sample to 
be in focus at one time. The SEM also produces images of high resolution, which means 
that closely spaced features can be examined at a high magnification. Preparation of the 
samples is relatively easy since most SEM one require the sample to be conductive. 
The combination of higher magnification, larger depth of focus, greater 
resolution, and easy of sample observation marks the SEM one of the most heavily used 
instruments in research areas today. 
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4.2.2. PROXIMATE CHEMICAL ANALYSIS OF A DRUG 
 Methodology for chemcial analysis 
Preparation of Extract: 
• Add 5 gm of the Jalamanjari chendooram to 50ml of distilled water.  
• Boil the solution for 20 minutes, cool and then filter.  
• Use the Extract for the following tests. 
 
Table 4.2.2 Methodology for chemcial analysis  
S.No Experiment Observation Inference 
1. 
Test for reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, then 
boil for two minutes 
Absence of Green / 
Yellow / Red PPT 
Abesence of 
Reducing Sugar 
2. 
Test for Starch : 
To 5 ml of extract add 2ml of acetic 
acid and then add few drops of N/50 
Iodine Solution. 
Absence of Blue 
Colour 
Absence of Starch 
3. 
Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate Solution. 
Absence of Violet or 
Purple Colour 
Absence of 
Proteins 
4. 
Test for amino Acid : 
Place  2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same 
and allow to dry. 
Absence of  Violet 
Colour 
Absence of 
Amino Acid 
5. 
Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch’s reagent. 
Absence of  Yellow 
PPT 
Absence of  
Albumin 
6. 
Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution and 
2ml of concentrated Nitric Acid. 
Presence of Yellow 
PPT 
Presence of 
Phosphate 
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S.No Experiment Observation Inference 
7. 
Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
Presence of White 
PPT 
Presence e of 
Sulphate 
8. 
Test for Chloride :  
Add 2ml of extract to dilute nitric 
acid till the effervescence ceases. 
Then add 2 ml of Silver Nitrate 
Solution. 
Presence of Cloudy 
White PPT 
Presence of 
Chloride 
9. 
Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thio cynate solution and 
add 2ml of concentrated Nitric 
Acid. 
Presence of Red 
Colour 
Presence of Iron 
10. 
Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
Absence of White 
PPT 
Absence of 
Calcium 
11. 
Test for Sodium : 
Make a paste with 2 pinches of the 
sample with Hcl and Introduce it 
into the blue flame.  
Absence of Yellow 
Flame 
Absence of 
Sodium 
12. 
Test for Potassium : 
Add a pinch of the sample to 2 ml 
of Sodium Nitrate Solution. Then 
add 2ml of Cobal Nitrate in 20% 
acetic acid. 
Absence of Yellow 
PPT 
Absence of 
Potassium 
13. 
Test for Zinc : 
To 2ml of extract, add few drops of 
Sodium Hydroxide. 
Absence of White 
PPT 
Absence of Zinc 
14. Test for Magnesium : 
To 2ml of extract, add few drops of 
Sodium Hydroxide Solution 
Absence of White 
PPT 
Absence of 
Magnesium 
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S.No Experiment Observation Inference 
15. 
Test for Alkaloids : 
a. To 2ml of extract, add 2ml of 
Potassium Iodide Solution 
b. To 2ml of extract add 2ml of 
Picric Acid. 
c. To 2 ml of extract add 2ml of 
Phosphotungstic Acid. 
Absence of 
Red Colour 
 
Absence of 
Yellow Colour 
 
Absence of  
White PPT 
 
Absence of 
Alkaloids 
 
Absence of 
Alkaloids 
Absence of 
Alkaloids 
16. 
Test for Tannic Acid : 
To 2ml of extract add 2 ml of Ferric 
Chloride Solution 
Absence of  
Black PPT 
Absence of 
Tannic Acid 
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4. 3. TOXICITY STUDY OF JALAMANJARI CHENDOORAM 
4.3.1. PROCEDURE OF ACUTE TOXICITY STUDY: 
Animals:  
Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of 
the Institute animal ethics committee and obtained from Vels University, Chennai. They 
were fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. The animals were acclimatized for one week 
under laboratory conditions.  
 
Acute Toxicity Study-OECD 425 Guidelines 
Acute oral toxicity test for the Jalamanjari Chendooram was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. The 
test substance is administered in a single dose by gavage using a stomach tube or a 
suitable intubation cannula. The fasted body weight of each animal is determined and the 
dose is calculated according to the body weight. After the substance has been 
administered, food was withheld for a further 2 hours in mice. The animals were 
observed continuously for the first 4 h and then each hour for the next 24 h and at 6 
hourly intervals for the following 48 h after administering of the test drug, to observe any 
death or changes in general behaviour and other physiological activities. Single animals 
are dosed in sequence usually at 48 h intervals. However, the time interval between 
dosing is determined by the onset, duration, and severity of toxic signs. Treatment of an 
animal at the next dose was delayed until one is confident of survival of the previously 
dosed animal.  
 
Observation of toxicity signs: General behavior, respiratory pattern, cardiovascular 
signs, motor activities, reflexes, change in skin and fur, mortality and the body weight 
changes were monitored daily. The time of onset, intensity, and duration of these signs, if 
any, was recorded 
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4.3.2 SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex (3+3) rats were 
divided into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were administered 
daily with the Jalamanjari Chendooram (p.o.) for 28 days at a dose of 25, 50 and 
100mg/kg respectively. The animals were then observed daily for gross behavioural 
changes and any other signs of subacute toxicity. The weight of each rat was recorded on 
day 0 and weekly throughout the course of the study, food and water consumption per rat 
was calculated. At the end of the 28 days they were fasted overnight, each animal was 
anaesthetized with diethylether, following which they were then dissected and blood 
samples were obtained by cardiac puncture into heparinised tubes. The blood sample 
collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to separate the 
serum and used for the biochemical assays.  
 
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis, glucose, creatinine, total 
protein, albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase 
(ALP)) were automatically determined using autoanalyzer. 
 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancreas, Lung, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all 
rats to visually detect gross lesions, and weighed to determine relative organs’ weights 
and preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
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Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-
Kramer Multiple Comparison Test using GraphPad Instat-V3 software. P values < 0.05 
were considered significant. 
 
4.4. DIURETIC ACTIVITY OF JALAMANJARI CHENDOORAM IN RATS 
Evaluation of Diuretic activity:  
 The screening was performed on healthy rats. Frusemide (20 mg/kg) was used as 
reference standard and Jalamanjari Chendooram were dissolved in saline solution for 
administration while normal saline (25 ml/kg) was used as vehicle. The rats were divided 
in 4 groups each containing 6 rats (n = 6). Rats were kept for fasting for 18 hrs before the 
study.  
 The control group received normal saline and test groups received 25 and 
50mg/kg of Jalamanjari Chendooram dissolved in normal saline. The doses of 
Jalamanjari Chendooram were decided on the basis of acute toxicity study. The doses 
were given by oral route and rats were kept in specially designed metabolic cages for the 
collection of urine for 6 hrs. The urine volume during 6 hrs is measured and urine 
electrolyte estimation was carried out for Na+, K+ using flame photometer and Cl- was 
estimated by titration. 
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Fig.4.4 Evaluation of Diuretic activity of Jalamanjari Chendooram 
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4.5. CLINICAL STUDY OF JALAMANJARI CHENDOORAM 
Objectives 
 To evaluate the Diuretic activity of Jalamanjari chendooram. 
 To explore the efficacy of in patients with Oedema, Hypertension, Urolithiasis. 
Design of the study 
Open clinical trial phase II B 
Study centre 
Arignar Anna Government Hospital of Indian Medicine and Homeopathy, 
Arumbakkam, Chennai –106. 
Study participants 
Both men and women and members of all races and ethnic groups are eligible for 
this trial. Treatment will be administered on an inpatient/outpatient basis. The patients 
will be selected from the In-patient and Out-patient department of Arignar Anna 
Government Hospital of Indian Medicine and Homeopathy, Chennai – 106. 
Number of subjects 
Number of participants were 50. 
Registration process 
To register a patient, the following documents were completed by the investigator. 
 Copy of required laboratory tests 
 Signed patient consent form 
 Other appropriate forms (e.g., Eligibility Screening Worksheet, Registration 
Form). 
The investigator will then verify eligibility and will assign a patient study number, 
drug dose and register the patient on the study. 
 
Criteria for inclusion 
Patients with Oedema, Hypertension, Urolithiasis are eligible for entry to the trial 
if the following criteria are satisfied. 
The criteria of inclusion are: 
 Oedema of lower extremity 
 Raised systolic and diastolic blood pressure ≥140/90. 
 Pain present in the either/both loins. 
 Patients with known urolithiasis with USG reports. 
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 Co operative patients 
 The previous drug regimen if any have been with held for 24 hours before 
the clinical trial. 
Criteria for exclusion 
 Severly ill patients. 
 AIDS 
 Malignancy 
 Pregnant and lactating women 
 TB 
 Cardio vascular disorder 
 Age below 10 years 
 Syphilis 
Withdrawal Criteria 
Patients were removed from study when any of the criteria listed below applies. 
The reason for study removal and the date the patient will be removed must be 
documented in the Case Report Form. 
In the absence of treatment delays due to adverse events, treatment may continue for 2 
cycles or until one of the following criteria applies: 
 Disease progression, 
 Deterioration of vital signs with cardiac, respiratory, hepatic, renal and CNS 
changes. 
 Intercurrent illness that prevents further administration of treatment, 
 Unacceptable adverse event(s), 
 Patient decides to withdraw from the study, or  
 General or specific changes in the patient’s condition render the patient 
unacceptable for further treatment in the judgment of the investigator. 
Routine examination and assessment 
The full details of history and physical examination of the patients is to be 
recorded as per the proforma. The clinical assessment will be done initially at the end of 
every week during treatment and at the end of the follow up. The laboratory investigation 
and the physiological parameters will be recorded initially at the end of the treatment and 
at the end of follow up as per the proforma. 24hrs urine volume estimation will be done 
in all patients before and after the intake of the drug 
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Trial drug 
Jalamanjari Chendooram 
Dosage 
Dose will be fixed after finding the LD50. 
Duration of trial 
Study Period: 7weeks with 2 months follow up. 
Total duration: 2 months 
Treatment plan 
Administration of the drug: 
 Form of the medicine  :  Chendooram 
 Route of Administration : Enteral 
 Dose    : 200mg 
 Times of Administration : Two times a day; after food 
 Duration   : 3-7 weeks 
Diet restriction and medical advice: 
 The patients will be instructed to follow easily digestible foods. 
 They will be advised to take tender coconut, and vegetables like radish, juice of 
plantain stem. Avoid bitter gourd, agathi greens, brinjal, and non-vegetarian diet. 
 The patient will advise to avoid cold damp climate. 
 The patient will be advised to take rest.  
 The clinical improvement will be observed and recorded daily in the proforma of 
case sheet. 
Trial conduct 
This study was conducted in compliance with the protocol approved by the 
Institutional Review Board, and according to Good Clinical Practice standards. No 
deviation from the protocol was implemented without the prior review and approval of 
the IRB except where it may be necessary to eliminate an immediate hazard to a research 
subject. In such case, the deviation was reported to the IRB  
Classification of results 
1. Good Response 
Relief of Symptoms above 75% and improvement towards normalcy in laboratory           
parameters. 
2. Fair Response 
50% to 75% relief in symptoms. Significant improvement in laboratory           
parameters. 
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3. Poor Response 
25% to 49% relief in symptoms and minimal improvement in laboratory           
parameters. 
4. No Response 
No relief in symptoms and no significant improvement in laboratory parameters. 
Follow up 
Assessment was taken for every three days before treatment and after treatment. 
During this period clinical assessment and laboratory investigation was carried out. 
 
Statistical Analysis 
The data were tabulated and analyzed by students ‘T’ test. 
Ethical review 
This protocol and any amendments were submitted to the Govt siddha medical 
college Institutional Ethical Committee (IEC) for formal approval to conduct the study. 
The decision of the IEC concerning the conduct of the study was made in writing to the 
investigator. 
All subjects for this study were provided a consent form describing this study and 
providing sufficient information for subjects to make an informed decision about their 
participation in this study. This consent form was submitted with the protocol for review 
and approval by the IEC. The formal consent of a subject, using the IEC-approved 
consent form, was obtained before that subject is submitted to any study procedure. This 
consent form must be signed by the subject or legally acceptable surrogate, and the 
investigator-designated research professional obtaining the consent. 
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                    4.5.3 Clinical study on Jala manjari chendooram in in and out patients dept. for diuretic activity  
Sl.No. I.P. No. Name Age/ Sex Date of first visit Symptoms 
  Date of 
last visit 
 
Results
1. 1085 GOVINDARAJ 43/M 23.7.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing  3.8.2012 GOOD 
2. 1174 SHANTHI 52/F 1.8.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 18.9.2012 FAIR 
3. 1288 DEVAKI 57/F 16.8.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 30.8.2012 GOOD 
4. 1383 SAMUNDEE SWARI 56/F 30.8.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 1.10.2012 FAIR 
     5. 1430 KOLANJI 51/M 4.9.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 15.9.2012 GOOD 
6. 62 JEYARAMAN 60/M 24.9.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 3.11.2012 GOOD 
7. 77 POONGOTHAI 52/F 24.9.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 13.10.2012 GOOD 
8. 457 BEEVI 65 /F 20.11.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 14.12.2012 GOOD 
9. 483 NAGAVALLI 50/F 21.11.2012  Diziness, headache,loss of sleep,tiredness,difficulty in breathing 13.12.2012 GOOD 
10. 629 KAMALA 47/F 13.12.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 24.12.2012 FAIR 
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4.5.4 Clinical study on Jala manjari chendooram in in and out patients dept. for diuretic activity 
 
Sl.No. O.P. No. Name 
Age/ 
Sex 
Date of first 
visit Symptoms 
Date of last visit 
 
 
Results 
11. 3020 GEETHA 32/F 6.7.2012 Pain present in the loin radiating to groin,dizziness and tiredness present 22.9.2012 GOOD 
12. 1652 SEETHA 34/F 22.9.2012 Pain present in the rt loin ,nausea,dizziness ,tiredness present 05.11.2012 FAIR 
13. 3425 SAJISH 29/M 29.9.2012 Pain present in the loin  radiating to groin, hematuria, nausea, tiredness present 25.10.2012 GOOD 
14. 4359 VIJAYA 50/F 3.10.2012 Swelling& pitting present in lower extremity,tiredness, present 05.11.2012 GOOD 
15. 5043 HARISH  59/M 11.10.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 11.12.2012 GOOD 
16. 7034 MANIVASAKAM 50/M 14.10.2012 Swelling  pitting oedema  present in lower   extremity,tiredness 21.12.2012 GOOD 
15. 7050 SATHEESH  39/M 14.10.2012 Pain present in the rt loin ,nausea,dizziness ,tiredness present 11.12.2012 GOOD 
16. 7966 MANIKKAM 60/M 18.10.2012 Swelling  pitting oedema  present in lower   extremity,tiredness 11.11.2012 GOOD 
19. 7979 JEYA 29/F 18.10.2012 Swelling,  pitting oedema  present in lower   extremity,tiredness 18.12.2012 FAIR 
20. 8191 MISHBAH 62/F 19.10.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 24.11.2012 GOOD 
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1.5.5 Clinical study on Jala manjari chendooram in in and out patients dept. for diuretic activity 
 
Sl.No. O.P. No. Name 
Age/ 
Sex 
Date of first 
visit Symptoms 
Date of last 
visit 
 
 
Results 
 
21. 8199 GAYATHRI 32/F 19.10.2012 Pain present in the loin radiating to groin, dizziness and tiredness present 22.12.2012 GOOD 
22. 8252 FARITHA 34/F 20.10.2012 Pain present in the rt loin ,nausea, dizziness ,tiredness present 05.12.2012 FAIR 
23. 8325 MAHESH 29/M 20.10.2012 Pain present in the loin  radiating to groin, hematuria, nausea, tiredness present 25.12.2012 GOOD 
24. 8359 KAVYA 33/F 20.10.2012 Swelling & pitting present in lower extremity,tiredness, present 05.11.2012 GOOD 
25. 8601 BOOBESH 39/M 21.10.2012 Pain present in the rt loin ,nausea, dizziness ,tiredness present 11.12.2012 GOOD 
26. 8656 VIVEKAN 34/M 21.10.2012 Swelling  pitting oedema  present in lower extremity, tiredness 28.11.2012 GOOD 
27. 8706 REBECCA 41/F 22.10.2012 Swelling,  pitting oedema  present in lower   extremity, tiredness 30.12.2012 GOOD 
28. 8711 PREMA 50/F 22.10.2012 Swelling,  pitting oedema  present in lower extremity, tiredness 19.11.2012 FAIR 
29. 9999 JEYAMALA 39/F 29.10.2012 Swelling,  pitting oedema  present in lower   extremity, tiredness 18.12.2012 GOOD 
30. 942 SENTHILKUMAR 55/M 3.11.2012 Diziness, headache, loss of sleep, tiredness, difficulty in breathing 12.12.2012 FAIR 
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4.5.6. Clinical study on Jala manjari chendooram in in and out patients dept. for diuretic activity 
 
Sl.No. O.P. No. Name Age/ Sex Date of first visit Symptoms Date of last visit  Results
31. 1383 ANDAL 55/F 5.11.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 16.12.2012 FAIR 
32. 1382 MAHESHWARI 60/F 5.11.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 20.12.2012 FAIR 
33. 1683 SURYA 55/M 6.11..2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 20.12.2012 GOOD 
34. 1681 JEYARAM 45/M 6.11..2012 Pain present in the rt loin ,nausea,dizziness ,tiredness present 19.12.2012 GOOD 
35. 1938 SASIKUMAR 45/M 7.11.2012 Diziness, headache,loss of sleep,tiredness,difficulty in Breathing 31.12.2012 FAIR 
36. 1939 KAMATCHI 61/F 7.11.2012 Swelling  pitting of the oedema  present in lower extremity,tiredness 19.12.2012 GOOD 
37. 1940 MUTHURAMAN 52/M 7.11.2012 Swelling  pitting of the oedema  present in lower   Extremity,tiredness 21.12.2012 GOOD 
38. 1941 RAMANI 45/F 7.11.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 19.12.2012 GOOD 
39. 3682  JAARUBA 40/F 17.11.2012 Swelling  pitting of the oedema  present in lower   Extremity,tiredness 18.12.2012 FAIR 
40. 5405 BIJALI 32/F 24.11.2012  Pain present in the rt loin ,nausea,dizziness ,tiredness present 31.12.2012 GOOD 
 
 
  
131 
 
4.5.7 Clinical study on Jala manjari chendooram in in and out patients dept. for diuretic activity 
 
Sl.No. O.P. No. Name Age/ Sex Date of first visit Symptoms Date of last visit  Results
41. 5483 DANAM 55/F 24.11.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 16.12.2012 GOOD 
42. 5553 MAHESHWARI 60/F 25.11.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 28.12.2012 FAIR 
43. 5583 SURYA 55/M 26.11..2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 20.12.2012 GOOD 
44. 5681 JEYARAM 45/M 28.11..2012 Pain present in the rt loin ,nausea,dizziness ,tiredness present 19.12.2012 GOOD 
45. 5938 KUMAR 45/M 5.12.2012 Diziness, headache,loss of sleep,tiredness,difficulty in Breathing 31.12.2012 FAIR 
46. 5939 KAMALINI 61/F 5.12.2012 Swelling  pitting of the oedema  present in lower extremity,tiredness 29.12.2012 GOOD 
47. 6940 MUTHU 52/M 7.12.2012 Swelling  pitting of the oedema  present in lower   Extremity,tiredness 31.12.2012 GOOD 
48. 6941 RAMADEVI 45/F 7.12.2012 Diziness, headache,loss of sleep,tiredness,difficulty in breathing 29.12.2012 GOOD 
49. 7432  RUBY 40/F 08.12.2012 Swelling  pitting of the oedema  present in lower   Extremity,tiredness 28.12.2012 GOOD 
50. 7461 GOPI 32/M 08.12.2012  Pain present in the rt loin ,nausea, ,tiredness present 31.12.2012 FAIR 
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4.5.8.1. General Haematological Investigation 
Sl. 
No. 
I.P. 
No. Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm)          Hb(Gm) 
BL.UREA BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT         AT BT             AT 
BT AT ALB 
SU
G DEP 
AL
B SUG DEP 
P L E P L E 
1 
hr 
1hr   
1. 1085 GOVINDARAJ 48/M 8500 64 32 4 8600 51 44 5 12 11 9.0 9.3 27 28 NIL NIL NIL NIL NIL NIL 
2. 1174 SHANTHI 63/M 8800 62 33 5 9900 60 34 3 12 12 10 12.3 29 30 NIL NIL NIL NIL NIL NIL 
3. 1288 DEVAKI 50/M 6100 64 31 5 6300 51 44 5 10 14 11.0 11.6 35 37 NIL NIL NIL NIL NIL NIL 
4. 1383 SAMUNDEE SWARI 55/M 9800 57 38 5 9800 58 38 4 11 12 13.0 13.6 32 31 NIL NIL NIL NIL NIL NIL 
  5. 1430 KOLANJI 53/M 8300 52 41 7 9200 62 26 8 14 15 11.0 12.4 23 21 NIL NIL NIL NIL NIL NIL 
6. 62 JEYARAMAN 50/M 7600 63 34 3 8000 52 44 4 16 15 12.0 13.4 30 26 NIL NIL NIL NIL NIL NIL 
7. 77 POONGOTHAI 62/M 9400 57 36 7 10100 63 33 4 15 14 11.0 12.7 23 22 NIL NIL NIL NIL NIL NIL 
8. 457 BEEVI 52 /M 8700 59 35 6 8800 58 39 3 12 13 11.0 12.7 35 33 NIL NIL NIL NIL NIL NIL 
9. 483 NAGAVALLI 55/M 10400 63 31 6 9400 62 33 5 13 14 10.0 13.4 31 35 NIL NIL NIL NIL NIL NIL 
10. 629 KAMALA 55/M 7600 48 46 6 7800 55 40 5 11 12 12.0 14.0 25 24 NIL NIL NIL NIL NIL NIL 
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4.5.8.2. General Haematological Investigation 
Sl. 
No. O.P. No. Name Age/ Sex 
                                                                 4.5.8.2  HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) BL.UREA BT AT 
TC 
CU/mm 
DC TC 
CU/mm 
DC BT       AT     Hb(Gm) 
BT AT Alb Sug Dep Alb Sug Dep 
P L E P L E 1 hr 1hr BT AT 
11. 3020 GEETHA 32/F 7900 55 39 06 9500 57 39 4 30 14 9.0 9.3 23 22 NIL NIL OEC NIL NIL NIL 
12. 1652 SEETHA 34/F 7600 48 46 6 7800 52 43 5 14 13 10.2 10.1 34 33 NIL NIL NIL NIL NIL NIL 
13. 3425 SAJISH 29/M 9700 59 36 5 9430 65 30 5 13 24 10.6 10.6 33 35 NIL NIL OPC NIL NIL NIL 
14. 4359 VIJAYA 50/F 9700 63 29 8 9200 53 42 5 33 13 10.6 11.8 25 24 NIL NIL NIL NIL NIL NIL 
15. 5043 HARISH  59/M 7600 63 32 5 8000 51 45 4 16 15 12.0 13.4 30 26 NIL NIL OPC NIL NIL NIL 
16. 7034 MANIVASAKAM 50/M 9400 56 36 8 9100 60 36 4 17 14 11.0 12.8 23 22 NIL NIL OPC NIL NIL NIL 
17. 7050 SATHEESH  39/M 8700 57 37 6 9800 60 56 4 14 13 13.0 13.7 34 33 NIL NIL NIL NIL NIL NIL 
18. 7966 MANIKKAM 60/M 9800 63 31 6 9400 62 33 5 14 14 8.6 10.4 33 35 NIL NIL NIL NIL NIL NIL 
19. 7979 JEYA 29/F 9800 64 30 6 8500 52 44 4 12 11 9.0 9.8 29 30 NIL NIL NIL NIL NIL NIL 
20. 8191 MISHBAH 62/F 8600 62 33 5 9900 62 33 5 12 12 12.0 12.3 30 28 NIL NIL NIL NIL NIL NIL 
21. 8199 GAYATHRI 32/F 7100 64 31 5 8500 61 34 5 12 14 11.0 11.6 23 22 NIL NIL NIL NIL NIL NIL 
22. 8252 FARITHA 34/F 9800 59 36 5 9800 59 37 4 11 12 13.0 13.6 34 33 NIL NIL NIL NIL NIL NIL 
23. 8325 MAHESH 29/M 9200 52 39 9 9200 58 38 4 16 15 10.0 11.4 29 30 NIL NIL NIL NIL NIL NIL 
24. 8359 KAVYA 33/F 7800 57 38 5 7900 54 42 4 15 14 9.0 9.3 30 28 NIL NIL NIL NIL NIL NIL 
25. 8601 BOOBESH  39/M 9800 55 37 8 9800 55 43 1 13 12 10.2 10.1 23 22 NIL NIL NIL NIL NIL NIL 
26. 8656 VIVEKAN 34/M 9700 60 36 4 9800 58 37 5 14 13 10.6 10.0 34 33 NIL NIL NIL NIL NIL NIL 
27. 8706 REBECCA 41/F 8600 55 39 6 8700 56 38 6 15 14 10.8 13.1 29 30 NIL NIL OPC NIL NIL NIL 
28. 8711 PREMA 50/F 7200 55 39 6 8000 57 37 6 14 15 11.0 10.1 35 37 NIL NIL OPC NIL NIL NIL 
29. 9999 JEYAMALA 39/F 8400 61 36 3 9300 62 35 3 11 13 9.0 9.9 28 29 NIL NIL NIL NIL NIL NIL 
30. 942 SENTHILKUMAR 55/M 8700 5 35 6 8800 58 56 6 14 13 13.0 13.7 33 33 NIL NIL OPC NIL NIL NIL 
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g4.5.8.3. General Haematological Investigation 
Sl. 
No. O.P. No. Name Age/ Sex 
4.5.8.3   HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) BL.UREA BT AT 
TC 
CU/mm 
DC TC 
CU/mm 
DC BT       AT Hb(Gm) 
BT AT Alb Sug Dep Alb Sug Dep 
P L E P L E 1 hr 1hr BT AT 
31. 1383 ANDAL 55/F 9300 55 32 13 9500 55 35 10 15 14 9.0 9.6 23 22 NIL NIL NIL NIL NIL NIL 
32. 1382 MAHESHWARI 60/F 7600 48 46 6 7800 51 44 5 14 13 10.2 121 34 33 NIL NIL NIL NIL NIL NIL 
33. 1683 SURYA 55/M 8600 59 34 7 9430 65 32 3 13 24 10.6 10.6 33 35 NIL NIL OPC NIL NIL NIL 
34. 1681 JEYARAM 45/M 9200 53 40 7 9200 53 42 5 14 12 11.8 13.8 25 24 NIL NIL NIL NIL NIL NIL 
35. 1938 SASIKUMAR 45/M 7600 63 32 5 8000 52 44 4 13 15 12.0 13.4 30 28 NIL NIL OPC NIL NIL NIL 
36. 1939 KAMATCHI 61/F 9400 57 36 7 9100 60 36 4 15 14 12.0 12.7 23 22 NIL NIL OPC NIL NIL NIL 
37. 1940 MUTHURAMAN 52/M 8600 59 35 6 8900 60 54 6 14 13 13.0 13.7 34 33 NIL NIL NIL NIL NIL NIL 
38. 1941 RAMANI 45/F 9800 63 31 6 9400 62 33 5 12 14 10.0 124 33 35 NIL NIL NIL NIL NIL NIL 
39. 3682 JAARUBA 40/F 7800 64 32 4 8500 52 44 4 12 11 9.0 9.3 29 30 NIL NIL NIL NIL NIL NIL 
40. 5405 BIJALI 32/F 9600 62 31 7 9900 64 32 5 12 12 11.0 12.3 30 28 NIL NIL NIL NIL NIL NIL 
41. 5483 DANAM 55/F 6100 64 31 5 6300 51 44 5 12 12 11.0 11.6 23 22 NIL NIL NIL NIL NIL NIL 
42. 5553 MAHESHWARI 60/F 8800 61 34 5 9800 65 31 4 11 12 13.0 13.6 34 33 NIL NIL NIL NIL NIL NIL 
43. 5583 SURYA 55/M 9200 52 39 9 9200 58 38 4 16 15 9.0 11.4 29 30 NIL NIL NIL NIL NIL NIL 
44. 5681 JEYARAM 45/M 7800 55 38 7 7900 51 45 4 15 14 9.0 9.3 30 28 NIL NIL NIL NIL NIL NIL 
45. 5938 KUMAR 45/M 9800 55 39 6 9900 55 41 4 13 12 10.2 10.1 23 22 NIL NIL NIL NIL NIL NIL 
46. 5939 KAMALINI 61/F 7600 60 36 4 9800 60 35 5 14 13 10.6 10.0 34 33 NIL NIL NIL NIL NIL NIL 
47. 6940 MUTHU 52/M 7700 55 39 6 8700 62 34 4 15 14 10.4 13.1 29 30 NIL NIL OPC NIL NIL NIL 
48. 6941 RAMADEVI 45/F 8000 55 39 6 8000 57 37 6 14 15 9.0 10.8 35 37 NIL NIL OPC NIL NIL NIL 
49. 7432 RUBY 40/F 9200 61 36 3 9300 62 35 3 15 13 9.2 12.6 28 29 NIL NIL NIL NIL NIL NIL 
50. 7461 GOPI 32/M 8500 59 35 6 8800 59 37 4 14 13 11.0 13.7 34 33 NIL NIL OPC NIL NIL NIL 
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4.5.9. 24 Hrs Urine Volume before and after administration of                                           
Jalamanjari Chendooram 
 
S.no OP/IP.No Name Age/ Sex 
24 hrs urine volume 
Before 
treatment 
After 
Treatment 
1. 5852 Kumar 45/M 950ML 1300ML
2. 5807 Valliammal 55/F 1100ML 1960ML 
3. 8053 Ramadas 60/M 1400ML 2100ML 
4. 851 Misbara 57/F 1300ML 2500ML 
5. 2698 Malliga 60/F 1600ML 2850ML 
6. 2764 Manikkam 60/M 1100ML 1650ML 
7. 3228 Revathi 45/F 1000ML 1950ML 
8. 4000 Jayashree 35/F 1500ML 2100ML 
9. 4443 Vijayalakshmi 45/F 1000ML 2030ML 
10. 6290 Banumathi 59/F 1100ML 1930ML 
11. 7545 Anandan 53/M 950ML 2000ML 
12. 7590 Mohammed ehiya 61/M 1100ML 1600ML 
13. 7656 Subramanium 68/M 980ML 1800ML 
14. 8738 Shanthi 48/F 1250ML 1860ML 
15. 8830 Srinivasan 45/M 1350ML 1830ML 
16. 8856 Saghadev1 43/F 1540ML 2100ML 
17. 9197 Ragothaman 62/M 1450ML 1830ML 
18. 125 Shanthi 48/F 1340ML 1800ML 
19. 515 Vijayalakshmi 45/F 950ML 1400ML 
20. 528 Kanchana 60/F 945ML 1300ML 
21. 8199 Gayathri 32/F 1050ML 1500ML 
22. 8252 Faritha 34/F 1120ML 2395ML 
23. 8325 Mahesh 29/M 1300ML 2200ML 
24. 8359 Kavya 33/F 950ML 1950ML 
25. 8601 Boobesh 39/M 1100ML 2250ML 
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4.5.9. 24 Hrs Urine Volume before and after administration of                                           
Jalamanjari Chendooram 
S.no OP/IP.No Name Age/ Sex 
24 hrs urine volume 
Before 
treatment 
After 
Treatment 
26. 8656 Vivekan 34/M 900ML 1950ML 
27. 8706 Rebecca 41/F 1050ML 1700ML 
28. 8711 Prema 50/F 1400ML 2100ML 
29. 9999 Jeyamala 39/F 1250ML 2000ML 
30 942 Senthilkumar 55/M 2000ML 2980ML 
31. 1383 Andal 55/F 1200ML 1850ML 
32 1382 Maheshwari 60/F 850ML 1950ML 
33. 1683 Surya 55/M 1400 ML 1800 ML 
34. 1681 Jeyaram 45/M 950ML 1780ML 
35. 1938 Sasikumar 45/M 1630ML 2100ML 
36. 1939 Kamatchi 61/F 900ML 2100ML 
37. 1940 Muthuraman 52/M 1260ML 1750ML 
38. 1941 Ramani 45/F 1150ML 1600ML 
39. 3682 Jaaruba 40/F 1250ML 2100ML 
40. 5405 Bijali 32/F 950ML 1700ML 
41. 5483 Danam 55/F 1100 ML 1760 ML 
42. 5553 Maheshwari 60/F 1350 ML 1950 ML 
43. 5583 Surya 55/M 1400 ML 2100 ML 
44. 5681 Jeyaram 45/M 900 ML 1850 ML 
45. 5938 Kumar 45/M 1250 ML 2200 ML
46. 5939 Kamalini 61/F 950 ML 1500 ML 
47. 6940 Muthu 52/M 1000 ML 2000 ML 
48. 6941 Ramadevi 45/F 1450 ML 2350 ML 
49. 7432 Ruby 40/F 1150 ML 2400 ML 
50. 7461 Gopi 32/M 1000 ML 1500 ML 
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5. RESULTS AND DISCUSSION 
 
4.2.2.1 PHYSICO-CHEMICAL ANALYSIS: 
 
S.No Parameter Mean Value 
1.  Loss on Drying at 105°C 6.6 % 
2.  Total Ash  81.55 % 
3.  Acid insoluble Ash   14.9 % 
4.  Particle size Completely passes 
through sieve no.44 
5.  pH 8.5 
 
 
 
4.2.2.2. FTIR Results: 
 
 
 
Fig.4.2.2.2. FTIR Graph 
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                Table 4.2.2.2 FTIR results 
Frequency bands Functional Group 
3446.3 Alcohol/Phenol O-H Stretch 
2925.3 Carboxylic Acid O-H Stretch 
2853.7 Carboxylic Acid O-H Stretch 
2363.8 Phosphonates 
2344.1 Phosphonates 
2116.1 Alkynyl C=C Stretch 
1636.1 Aromatic C=C Bending 
1384.0 Alkyl –methyl 
1154.0 Alcohols – tertiary 
1018.2 Fluoro alkanes – ordinary 
887.5 Aromatic- meta disubstituted benzene C─H 
824.6 Aromatic-para disub. benzene C─H 
810.9 Aromatic-para disub. Benzene C─H 
739.9 Chloroalkanes C-X 
658.6 Chloroalkanes C-X 
597.5 Bromoalkanes or chloroalkanes C-X 
537.4 Bromoalkanes C-X 
 
These bands indicate the presence of amine, carboxylic acid, alkynes and 
aromatic functional groups. 
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4.2.2.3. SCANNING ELECTRON MICROSCOPE (SEM): 
 
For drug delivery biodegradable nanoparticle formulations are needed as it is the 
intention to transport and release the drug in order to be effective. 
 
4.2.2.4. CHEMICAL ANALYSIS OF JALAMANJARI CHENDOORAM 
S.NO CHEMICALS RESULT  [ + ] / [ − ] 
1. SULPHATE + 
2. CHLORIDE + 
3. PHOSPHATE + 
4. IRON + 
 
The chemical analysis shows the presence of anions namely phosphate, sulphate, 
chloride radicals enhances the osmotic regulation of the cells and its metabolism. 
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4.3TOXICITY STUDY RESULTS 
 
 All the animals from control and all the treated dose groups up to 100 mg/kg 
survived throughout the dosing period of 28 days. No signs of major or significant 
intoxication were observed in animals from lower dose groups. Animals from all the 
treated dose groups exhibited comparable body weight gain with that of controls 
throughout the dosing period of 28 days. Food consumption of control and treated 
animals was found to be comparable throughout the dosing period of 28days. 
Ophthalmoscopic examination, conducted prior to and at the end of dosing period on 
animals from control and all the treated dose groups did not reveal any abnormality. 
  
Haematological analysis revealed no significant abnormalities attributable to the 
treatment. Biochemical analysis conducted at the end of the dosing period, revealed no 
remarkable abnormalities attributable to the treatment. Functional observation tests 
conducted at termination revealed no abnormalities. Urine analysis, conducted at the end 
of the dosing period revealed no abnormality attributable to the treatment. Organ weight 
data of animals sacrificed at the end of the dosing period was found to be comparable 
with that of respective controls. Gross pathological examination did not reveal any 
abnormality. Histopathological examination did not reveal any abnormality. 
 
Conclusion 
 In Conclusion, no toxic effect was observed upto 50mg/kg of Jalamanjari 
Chendooram treated over a period of 28 days. So, it can be concluded that the 
Jalamanjari Chendooram can be prescribed for therapeutic use in human with the dosage 
recommendations of upto 50mg/kg body weight p.o. 
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Study of Jalamanjari Chendooram 
 
Table 4.3.1: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 500 + - - + - + - - - - - - - - - - - - - - 
2 1000 + + - + - + - + - - - - - - - - - + - + 
3 2000 + + - + - + - + + - - - - + - - - + + + 
 
1. Alertness 2.Aggressiveness 3. Pile erection 4.Grooming 5.Gripping 6. Touch Response 7. Decreased Motor Activity 8. Tremors  9. Convulsions 
10. Muscle Spasm 11. Catatonia  12. Muscle relaxant 13. Hypnosis  14.Analgesia 15.Lacrimation 16.Exophthalmos 17. Diarrhoea 18. Writhing   
19. Respiration 20. Mortality 
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4.4.1DIURETIC ACTIVITY OF JALAMANJARI CHENDOORAM IN 
RATS 
  Neither mortality nor any gross behavioural changes were observed during and 
after the treatment. The Jalamanjari Chendooram was found to be safe up to 500 mg/kg. 
Frusemide treated rats showed a significant increase in volume of urine and urinary 
excretion of sodium, potassium and chloride (p< 0.01) as compared to control while 
Jalamanjari Chendooram 50mg treated rats did not show any significant increase in 
urine volume but has high electrolyte excretion potential (p< 0.01).  
 
 Jalamanjari Chendooram 50mg/kg showed remarkable increase in volume of 
urine, urinary sodium, potassium or chloride. Diuretics relieve pulmonary congestion and 
peripheral edema. These agents are useful in reducing the syndrome of volume overload, 
including orthopnea and paroxysmal nocturnal dyspnoea. They decrease plasma volume 
and subsequently venous return to the heart. This decreases cardiac workload, oxygen 
demand and plasma volume, thus decreasing blood pressure. Thus, diuretics play an 
important role in hypertensive patients.  
 
Conclusion 
 On the basis of the results of present investigation, we can conclude that ash and 
successive Jalamanjari Chendooram might be good diuretics. In present study, no 
lethality was observed at least for the dose and duration used. However, advanced 
toxicological studies remain to be performed in rodents. It remains necessary to study 
eventual adverse effect of this Jalamanjari Chendooram such as alteration of some 
metabolic and hormonal parameters.  
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4.3.2.   Histopathological Features 
Bone  
 Fig.  4.3.2.1.1 Lowdose   Fig. 4.3.2.1.2 Middose    Fig. 4.3.2.1.3 Highdose 
 
Brain 
   Fig.  4.3.2.2.1 Lowdose    Fig.  4.3.2.2.2 Middose    Fig.  4.3.2.2.3 Highdose 
 
Heart 
 
  Fig.  4.3.2.3.1 Lowdose 
 
  Fig.  4.3.2.3.2 Middose    Fig.  4.3.2.3.3 Highdose 
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Intestine 
 
  Fig.  4.3.2.4.1 Lowdose     Fig.  4.3.2.4.2 Middose    Fig.  4.3.2.4.3 Highdose 
 
Kidney 
 
  Fig.  4.3.2.5.1 Lowdose Fig.  4.3.2.5.2 Middose Fig.  4.3.2.5.3 Highdose 
 
Liver 
 
Fig.  4.3.2.6.1 Lowdose Fig.  4.3.2.6.2 Middose Fig.  4.3.2.6.3 Highdose 
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Lung  
    Fig.  4.3.2.7.1 Lowdose      Fig.  4.3.2.7.2 Middose    Fig.  4.3.2.7.3 Highdose 
 
Ovary 
   Fig.  4.3.2.8.1 Lowdose      Fig.  4.3.2.8.2 Middose     Fig.  4.3.2.8.3 Highdose 
 
Pancreas 
 
Fig.  4.3.2.9.1 Lowdose Fig.  4.3.2.9.2 Middose     Fig.  4.3.2.9.3 Highdose 
 
 
148 
 
Spleen 
 
     Fig.4.3.2.10.1Lowdose     Fig. 4.3.2.10.2 Middose
 
      Fig. 4.3.2.10.3 Highdose 
 
Stomach 
     Fig.4.3.2.11.1Lowdose    Fig. 4.3.2.11.2 Middose     Fig. 4.3.2.11.3 Highdose 
Testis 
 
    Fig.4.3.2.12.1Lowdose  Fig. 4.3.2.12.2 Middose          Fig. 4.3.2.12.3 Highdose 
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urine per day 6pts excreted an increaseof 901- 1000ml,other 4 pts excreted an increase 
1001-1100ml of urine per day, 6 pts excreted an increase 1100ml of urine per day. 
Among 23 SHT patients, 13 out of 23 patients were relieved from headache, out 
of 15 oedema patients, 12 were relieved from swelling of the legs, out of 23 SHT patients 
19 were relieved from dizziness, out of 23 SHT patients 18 were relieved from loss of 
sleep, out of 12 urolithiatic patients 11 were relieved from pain in the loins.  
 The results revealed that the drug possess 70% good relief, 30% fair relief.  
                                      
Table 4.5.13 Statistical analysis 
Descriptive statistical analysis for improvement of urine output in patients 
Paired “t” test result: Table. 4.5.13A  
“p” value & statistical significance: 
Treatment No. of patients Mean S.D S.E.M 
Before treatment 50 1182.3 238.1 33.67 
After treatment 50 1954.18 334.92 47.85 
Table. 4.5.13A showing Paired “t” test result 
 
From the table we calculated the descriptive statistics like Mean, S.D & S.E.M of 
Mean for the improvement score before and after treatment. 
“t” Table: Table 4.5.13B 
t-Table S.D “t” Value “p” Value 
Pre vs Post 38.66 19.8697 0.0001 
 
The two-tailed P value is less than 0.0001.By conventional criteria; this difference 
is considered to be extremely statistically significant. 
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Discussion: 
 The clinical study was carried out with 50 patients.  Three groups of cases were 
studied for the diuretic effect of Jalamanjari chendooram, 46% Systemic Hypertension, 
30% Oedema, 24% Urolithiasis patients were included in this clinical trial. The patients 
laboratory examination before and after the treatment, including urine volume were noted 
The cumulative analysis revealed significant increase in the levels of 24 hrs urine 
volume. The increased urine volume levels established the diuretic effect of the trial drug 
Jalamanjari chendooram.  
In the pharmacological Study Jalamanjari Chendooram 50mg/kg showed 
remarkable increase in volume of urine and in present study, no lethality was observed. 
 In clinical study there was a marked improvement in signs & symptoms of the 
patients. The results revealed that the drug possess 70% good relief, 30% fair relief. It 
shows the excellent safety and good efficacy of Jalamanjari Chendooram both in Pre 
clinical and clinical studies. So the trial drug Jalamanjari Chendooram has the potential 
to be used as diuretic in the treatment of various diseases.  
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6. CONCLUSION 
 
 Jalamanjari Chendooram is a unique type of medicine, which is made up by a 
special type of preparation method erippu chendooram in siddha system which is written 
by the great Siddhar Yoogi muni in ‘Yoogi karisal 151’. 
 
  Literature survey, Chemical analysis, Physico chemical analysis, showed the 
efficacy of Jalamanjari Chendooram as a diuretic. Since many of the constituents in the 
medicine according to the literature review has got a diuretic property Jalamanjari 
Chendooram is one among the gifted medicines in the siddha system. The finding of the 
pre clinical study suggests that Jalamanjari Chendooram is an effective diuretic. 
 
 Jalamanjari Chendooram had remarkable effect in increasing the 24hrs urine 
volume in patients before and after treatment. 
 
In clinical trials, the drug shows the significant improvement in 70% of patients 
  
Thus the siddha science based Jalamanjari Chendooram had been proved by the modern 
scientific parameters as an efficient diuretic. 
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7. SUMMARY 
 
The poly mineral drug Jalamanjari Chendooram was prepared as per the 
traditional way. The author subjected the drug to various studies. 
 
Jalamanjari Chendooram was selected for this study to establish the safety and 
efficacy of the drug as a diuretic. 
 
The information about the drug, was collected from various text books, Literature 
were referred. From them, the author came to an idea about the drug and its efficacy as a 
diuretic. 
 
A brief description about Siddha aspect of the minerals used in the preparation of 
Jalamanjari Chendooram characters was given. 
  
 Acute and Sub acute toxicological studies show strong evidence of the nontoxic 
effect of the Jalamanjari Chendooram. The results showed Jalamanjari Chendooram is 
safe and efficient diuretic Siddha medicine. 
 
The pharmacological analysis showed that the drug has got significant diuretic 
activity. 
 
 In clinical study, the drug has showed improvement in 70% of cases. 
 
The patients responded well from the beginning of the treatment and there were 
no adverse effects during the entire clinical study. 
 
This present study suggests that Jalamanjari Chendooram has remarkable 
medicinal value as a diuretic.   
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